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ABSTRACT
The Diabetic Heart: Examination of the Inner Mitochondrial Membrane
Tara L. Croston
Cardiovascular complications, such as diabetic cardiomyopathy, are the primary
cause of morbidity and mortality in patients with diabetes mellitus. The hyperglycemic
environment associated with diabetes mellitus has been shown to induce the
mitochondrial dysfunction contributing to diabetic cardiomyopathy. The examination of
mitochondrial function is further complicated by the existence of two spatially and
functionally distinct cardiac mitochondrial subpopulations, the subsarcolemmal (SSM)
interfibrillar (IFM) mitochondria. These two pools of mitochondria respond differently to
pathologic stimuli, such as diabetes mellitus. Targeted by the deleterious effects of
diabetes mellitus, the inner mitochondrial membrane (IMM) is composed of a specific
lipid environment that houses many critical processes and machinery required for
proper mitochondrial function. The impact of diabetes mellitus on the IMM, including the
lipids and processes housed within, is not completely understood in type 1 diabetic
setting, and has not been assessed in mitochondrial subpopulations from type 2
diabetic human heart. The goal of the studies included in this dissertation was to
understand the importance of IMM preservation during diabetes mellitus and to translate
rodent mitochondrial dysfunction that occurs during diabetic cardiomyopathy to the
human diabetic heart. FVB mice (20-25 grams) were made type 1 diabetic through
multiple low dose injections of streptozotocin (STZ) for five consecutive days. Five
weeks post diabetic onset, hearts were excised and mitochondrial subpopulations were
isolated. For the type 2 diabetic human population, right atrial appendages were excised
during coronary artery bypass grafting or valve replacement surgery, from which
mitochondrial subpopulations were isolated. Cardiolipin, an essential phospholipid
contained within the IMM, was shown to be decreased during a type 1 diabetic insult;
however the mechanism attributing to this decrease in unknown; therefore, the
cardiolipin biosynthetic pathway was evaluated in the type 1 diabetic mouse model.
Results indicated decreased cardiolipin synthase protein content and activity in the
diabetic IFM. The data also revealed a decrease in two critical cardiolipin-ATP synthase
associations, which could potentially contribute to the observed decreased ATP
synthase activity in the diabetic IFM, all of which are located in the IMM. Within the type
1 diabetic mouse model, a key constituent involved in protein import, glucose regulated
protein 75, has been reported to be decreased and when overexpressed, preliminary
data depicted mitochondrial functional restoration in the diabetic IFM. Mitochondrial
dysfunction, as evidenced by decreased state 3 mitochondrial respiration, as well as
decreased electron transport chain complex I and complex IV activity was observed in
the SSM of type 2 diabetic human heart, compared to the non-diabetic heart. These
results suggest for the first time, that mitochondrial dysfunction is present in the type 2
diabetic human heart and that SSM impacted to a greater extent than IFM. Taken
together, the results of these studies demonstrate the importance of preserving the IMM
structure to alleviate mitochondrial dysfunction associated with the diabetic heart, as
well as understanding the effect of diabetes mellitus on human cardiac mitochondrial

subpopulations. Further, the preliminary results highlight therapeutic strategies involving
protein import constituents on the ability to attenuate mitochondrial dysfunction that
occurred during a diabetic insult.
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SPECIFIC AIMS

Cardiovascular complications, such as diabetic cardiomyopathy, are the primary
cause of heart failure in patients with diabetes mellitus (3). The hyperglycemic
environment produced during diabetes mellitus contributes to diabetic-associated
mitochondrial dysfunction (8, 9). A critical component in the mitochondrion is the inner
mitochondrial membrane (IMM) which contains a signature lipid environment required
for proper mitochondrial function. Cardiac mitochondria consist of two spatially distinct
subpopulations: subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria
(IFM), of which no group has currently examined in the diabetic human heart.

Cardiolipin, an integral phospholipid located in the IMM, has been shown to play
a vital role in mitochondrial bioenergetics (1). We have previously observed decreased
cardiolipin content during a type 1 diabetic insult (6), specifically in IFM (5); however,
the mechanisms underlying this loss are unknown. Proteomic data indicates decreased
abundance of mitochondrial proteins in the diabetic heart, which include IMM proteins
(2, 7), such as electron transport chain (ETC) proteins associated with cardiolipin. Our
laboratory has suggested a correlation between the proteomic decrements to a
decrease in nuclear-encoded protein import into the mitochondria during a type 1
diabetic insult (2). Mitochondrial glucose regulated protein 75 (Grp75), an essential
component of nuclear-encoded protein import, was also decreased in diabetes mellitus
(2, 4). Currently, the mechanisms contributing to cardiolipin loss and the therapeutic
benefit of molecular gene manipulation on a key mitochondrial protein import constituent
during diabetes mellitus are currently unclear.
xv

Our long term goal is to understand the importance of IMM preservation during
diabetes mellitus and to translate rodent mitochondrial dysfunction that occurs during
diabetic cardiomyopathy to the human diabetic heart. The objectives of this
dissertation were to: (1) to determine how the cardiolipin biosynthesis pathway and
cardiolipin-protein interactions are impacted by type 1 diabetes mellitus; (2) to
determine

the

therapeutic

value

of

mitochondrial

Grp75

overexpression

on

mitochondrial protein import during a type 1 diabetic insult; and (3) to examine how
mitochondrial subpopulations in the human heart are affected by diabetes mellitus. The
central hypothesis of this dissertation was that the mitochondrion is negatively
impacted by diabetes mellitus, leading to deleterious effects to the IMM and
compromising the proteins associated with cardiolipin and protein import, which will
translate to the diabetic human heart. The central hypothesis of this study will be
examined by testing the following Specific Aims:

Specific Aim I: Determine the effect of a type 1 diabetic insult on the biosynthesis of
cardiolipin, and evaluate key cardiolipin -protein interactions in the IMM. Further,
determine if the effect is mitochondrial-subpopulation specific.
Our working hypothesis is that type 1 diabetes mellitus decreases cardiolipin
content, due to deficient cardiolipin synthase, and that this lack of cardiolipin decreases
its association with vital proteins in the IMM, specifically ATP synthase. Further, these
effects will be most pronounced in IFM.

xvi

Specific Aim II: Examine the therapeutic value of Grp75 overexpression on
mitochondrial function following a type 1 diabetic insult. Further, determine if the effect
is mitochondrial-subpopulation specific.
A novel transgenic mouse model created in our laboratory will be used to
examine the role of Grp75 during diabetes mellitus. Our working hypothesis is that
Grp75 overexpression will preserve mitochondrial function through a mechanism of
enhanced protein import during a type 1 diabetic insult. These effects will be most
pronounced in IFM.

Specific Aim III: Evaluate mitochondrial dysfunction in human heart tissue and
examine the effects of diabetes mellitus on mitochondrial subpopulations.
Our working hypothesis is that diabetes mellitus causes abnormalities in
mitochondria, characterized by decreased size, function and protein import. The
decreased protein import potentially leads to mitochondrial proteome decrements and
ultimately resulting in mitochondrial dysfunction associated with diabetes mellitus.

Our rationale for the research conducted for this dissertation is based on the
importance of preserving the IMM structure to alleviate mitochondrial dysfunction
associated with the diabetic heart, as well as understanding the effect of diabetes
mellitus on human cardiac mitochondrial subpopulations. The anticipated outcomes
were intended to highlight therapeutic strategies involving cardiolipin synthesis and
protein import on the ability to attenuate mitochondrial dysfunction that occurred during
a diabetic insult. The research gathered from this dissertation was innovative because

xvii

the mechanisms elucidating mitochondrial dysfunction during a diabetic insult have not
been previously examined, especially in a translational model, and several of the
methodologies utilized were developed in our laboratory. At the completion of this
dissertation, we were able to highlight potential at-risk targets within the IMM during a
diabetic insult and determine the therapeutic benefit of overexpressing a key constituent
in the protein import machinery. The results gathered has advanced our understanding
of the mechanisms involved in both type 1 and type 2 models, from which therapeutic
strategies can be developed.
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Chapter 1:
Literature Review

1.1 Diabetes Mellitus

Diabetes mellitus is a metabolic disease characterized by high blood glucose
levels and insulin deficiency. There are different types of diabetes mellitus, all of which
result in a hyperglycemic environment; however, they manifest differently. Type 1 and
type 2 are the more common forms of diabetes mellitus. A third form, called gestational
diabetes, occurs in pregnant women who have high blood glucose levels during
pregnancy (4). Other types of diabetes mellitus due to other causes also exists, such as
genetic defects in β-cell function and insulin action, different diseases or a drug and/or
chemical induction of the disease (5). Previously, the diagnosis of diabetes mellitus was
based on fasting plasma glucose or an oral glucose tolerance test; however, in 2010,
the American Diabetes Association included the assessment of glycated hemoglobin
(HbA1c) into the criteria used to diagnose an individual with diabetes mellitus (5). Table
1.1 summarizes the specific criteria used to diagnose diabetes mellitus.

Table 1.1. American Diabetes Association: Criteria for the diagnosis of diabetes
HbA1c

> 6.5% (Using a NGSP certified method and standardized
to the DCCT reference assay)

Fasting Plasma Glucose

> 126 mg/dL (No caloric intake for > 8 hours)

2-hour Plasma Glucose

> 126 mg/dL during an OGT test (Glucose load = 75 g
anhydrous glucose in dissolved water)

Random Plasma Glucose

> 200 mg/dL in patients with symptoms of hyperglycemia

Note: This table is from the American Diabetes Association (5). NGSP = National Glycohemoglobin
Standardization Program; DCCT = Diabetes Control and Complications Trial; and OGT = Oral Glucose
Tolerance
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1.1.1 Type 1 Diabetes Mellitus

Type 1 diabetes mellitus makes up about 5-10% of all cases and is characterized by
the lack of insulin production (136). Previously known as juvenile diabetes, insulindependent diabetes or type 1 diabetes mellitus is caused by pancreatic β-cell
autoimmune destruction and subsequently, results in the inability for insulin production
causing an insulin deficiency. This depletion in insulin levels results in the inability for
the body to maintain glucose homeostasis, producing the hyperglycemic environment
that is associated with diabetes mellitus. The rate of β-cell destruction is variable, with
the onset occurring quickly in infants and children, to slowly in adults (12). Some forms
of type 1 diabetes mellitus have no origination and are inherited, with these particular
patients having insulinopenia and an increased susceptibility to ketoacidosis (12).

Type 1 diabetes is known to affect a multitude of organs and systems, including
eyes, liver, kidney, nervous system, skeletal muscle, and the heart (45). The main
treatment for type 1 diabetes mellitus is glucose monitoring and insulin therapy, which
will aid in the utilization of glucose. Although type 1 diabetic patients are not normally
obese, diet and exercise allow the body to accept the insulin therapy more efficiently
and consequently, is recommended. Other potential treatments include cell-based
therapeutics that target immune cells in attempt to prevent against, or reverse, type 1
diabetes mellitus (14).

3

1.1.2 Type 2 Diabetes Mellitus

The more prevalent form of diabetes mellitus is classified as type 2, making
approximately 90-95% of cases. Also known as non-insulin dependent diabetes, Type 2
diabetes mellitus is characterized by insulin resistance and a β-cell secretory defect,
also resulting in a hyperglycemic environment (136). Patients with type 2 diabetes
mellitus are often obese; however, it is possible to be non-obese with this disease.
These particular patients may have an increased body fat percentage, distributed
mainly in the abdominal region (12). In contrast to type 1 diabetes mellitus, ketoacidosis
is not usually present. Type 2 diabetes mellitus is more common in African, Native, and
Asian Americans, as well as Latinos and the aged population (4).

Patients with type 2 diabetes mellitus frequently go undiagnosed because of the
slow disruption of the glucose homeostasis. These patients may have normal insulin
levels; however, when compared to the elevated levels of blood glucose, the insulin
levels are not high enough to compensate for the elevated blood glucose resulting in
insulin secretion deficiency. At the beginning stages of type 2 diabetes mellitus, patients
exhibit dyslipidemia and a lipoprotein pattern including increased triglyceride levels, low
high density lipoprotein cholesterol values and small, dense low density lipoprotein
particles (141). Dyslipidemia is a critical risk factor to target in attempt to prevent
cardiovascular disease in patients with type 2 diabetes.
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The main treatment of type 2 diabetes is diet and exercise to reduce the body
weight in obese patients and to improve glycemic control (141, 158). By lowering body
weight, blood glucose levels decrease; and therefore, the amount of insulin the
pancreas secretes would be sufficient to maintain glucose homeostasis. Insulin therapy
or medications that increase insulin sensitivity and/or decreased glucose production can
also serve as treatment for type 2 diabetes mellitus (120).

1.1.3 Significance

Patients with diabetes mellitus are at an increased risk for cardiovascular
complications, which are the leading cause of morbidity and mortality in patients with
diabetes mellitus (66). In 2011, 8.3% of the population in the United States was
diagnosed with diabetes mellitus. Every year, there are 1.9 million new cases diagnosed
in individuals 20 years old or older (4, 34). By the year 2030, the incidence of diabetes
mellitus is expected to reach 366 million (161). This vastly growing disease is quickly
becoming an epidemic; therefore, the evaluation and identification of the mechanisms
underlying the deleterious effects of diabetes mellitus can advance the biomedical field,
from which therapeutic strategies can be developed and implemented.
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1.2 Diabetic Cardiomyopathy

In 1999, Grundy et al. (70) suggested that the most common complication of
diabetes is cardiovascular disease. In the presence of hypertension and ischemic heart
disease, patients with diabetes mellitus have an increased risk to develop heart failure.
This development of heart failure can also occur in asymptomatic patients, without the
presence of the hypertension or heart disease, which is termed diabetic cardiomyopathy
(8, 21, 58, 122, 131). Characterized by cardiac contractile abnormalities and
independent of vascular pathogenesis, diabetic cardiomyopathy was first described by
Rubler et al. in 1972 (131) and has been associated with mitochondrial dysfunction (51,
70, 122, 136, 147). Studies have also reported direct mitochondrial dysfunction
associated with cardiac contractile dysfunction (62, 98) due to the decrease in ATP
production (143).

1.2.1 Cardiac contractile dysfunction

The deleterious effects to the heart caused by the hyperglycemic environment
associated with diabetes mellitus ultimately results in heart failure. Studies have
reported increased heart failure rates in individuals with diabetes mellitus, even after
correcting for covariables, such as age, hypertension, and coronary artery disease (11,
19, 109). Human studies have indicated increased left ventricular mass and systolic
dysfunction (51, 65, 144), which may contribute to the diabetic-associated decreased
cardiac function (21). Experimental data collected from animal models indicate
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contractile dysfunction presence as early as one week post diabetic induction (134).
Literature has also suggested that diastolic dysfunction precedes systolic dysfunction in
diabetic cardiomyopathy (18, 60, 100). In 2006, Galderisi stated that diabetic patients
often develop abnormal left ventricular relaxation while the systolic function is still
normal (64).

Previously, cardiac catheterization was used to assess left ventricular diastolic
function from which the rates of relaxation, filling and left ventricular wall stiffness was
measured (105). More recently, non-invasive conventional echocardiography and tissue
Doppler techniques have been used to identify and quantify diastolic dysfunction (57,
146, 171). In normotensive diabetic patients, left ventricular dysfunction was observed
by increased pre-ejection period and a shorter left ventricular ejection time using
conventional echocardiography (6). Impaired left ventricular relaxation and restrictive
filling patterns have been identified using Doppler echocardiography in diabetic patients
(64, 111). Carugo et al. observed increased left ventricular wall thickness and mass, as
well as a reduced E/A ratio (mitral peak velocity of early (E) and late (A) ventricular
filling) in normotensive diabetic patients (33). Dabkowski et al. reported decreased
cardiac function as determined by decreased rates of contraction, relaxation and
developed pressure in Langendorff – perfused diabetic mouse hearts (48). Studies
examining diabetic rats have shown decreased cardiac contractile performance in
perfused, working hearts (87, 151), including decreased systolic function as measured
by decreased speed and prolongation of cardiac contraction (59, 118). Regan et al.
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demonstrated decreased ventricular compliance with no change is systolic function in
diabetic dogs (121).

In the diabetic heart, increases in the polyol and hexosamine pathway flux,
advance glycation end products, and superoxide production have been reported to
contribute to the contractile dysfunction and are suggested to be induced by the
hyperglycemic environment (26). Along with hyperglycemia, the reduced insulin action
and hyperlipidemia has resulted in an increase in both oxidative stress and lipotoxicity,
as well as an alteration in calcium homeostasis (136).

1.2.2 Cardiac metabolism

Diabetes mellitus influences cardiac metabolism due to an altered substrate
supply and decreased insulin action (129). Normally, 70% of the ATP production in the
heart is derived from fatty acid oxidation compared to 30% of the energy derived from
glucose and lactate (8). In type 1 diabetic patients, glucose uptake in the heart is
normal, suggesting that the limiting factor is insulin (8). In type 2 diabetics, myocardial
GLUT4 is responsible for the translocation of glucose into the tissue in order for the
heart to derive energy through glucose oxidation. During the shift of substrate utilization,
GLUT4 content and translocation activity is decreased, reducing the rates of glucose
oxidation (164). Along with a decrease in glucose transport into the tissue, glucose
supply has also been reported to be decreased in isolated diabetic cardiomyocytes (40),
as well as in diabetic patients (112).
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Hyperglycemia causes increased circulating free fatty acids and triglycerides,
due to enhanced lipolysis and increased lipoprotein synthesis. Fatty acid transport
across the plasma membrane does not require any hormone, such as insulin; therefore,
intracellular fatty acids increase during diabetes mellitus, causing fatty acid oxidation,
which becomes the heart’s exclusive energy source (8). As diabetes develops, the
increased FA substrates activate peroxisome proliferator-activated receptor alphamediated signaling, leading to the transcriptional induction of enzymes involved in beta
oxidation (22). Peroxisome proliferator-activated receptor beta and AMP-activated
protein kinase are also activated by diabetes mellitus, which promotes fatty acid
utilization (8, 106) and turns on ATP generating processes, such as fatty acid oxidation
and glycolysis (75, 81).

Fatty acid oxidation is known to inhibit glycolysis and glucose oxidation. Along
with these inhibitions and decrease glucose uptake, calcium homeostasis is disrupted,
contributing to diabetic cardiomyopathy. The calcium homeostasis can also be altered
by decreased expression of ion transporters or the Na +/Ca+ exchanger, which has been
shown to take place during type 1 (76, 91) and type 2 diabetes (17) in animal models.

1.2.3 Oxidative stress

Oxidative stress is reflected by the body’s ability to balance between the
manifestation and removal of reactive oxygen species (ROS). The hyperglycemic
environment associated with diabetes mellitus, leads to an increase in ROS. Examples
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of ROS include superoxide, hydrogen peroxide and hydroxyl radicals. Research
previously published in a streptozotocin (STZ) type 1 diabetic mouse model suggested
an increased in superoxide production (48). The body defends against the increase in
ROS through an antioxidant defense system, which contains antioxidant enzymes that
either inhibit ROS from being formed or scavenges ROS in attempt to maintain
homeostasis. The antioxidant levels in the heart are lower in the presence of
hyperglycemia, rendering the heart more susceptible to ROS damage (129).

Literature has suggested that the polyol and hexosamine pathway flux, advance
glycation end products, and activation of protein kinase C (26) are reported to be
increased in the diabetic heart due to an increase in ROS production. Because much of
the damage during diabetes mellitus is caused by increased ROS levels, strategies to
decrease ROS and subsequent oxidative damage are suggested to have therapeutic
potential (69). One study reported that different antioxidants administered to GotoKakizaki rats, a type 2 diabetic rodent model, did not reverse the diabetic phenotype
(114). In contrast, mitochondrial phospholipid hydroperoxide glutathione peroxidase
overexpression has been shown to improve cardiac and mitochondrial function during a
type 1 diabetic insult in mouse hearts (15). Taken together, studies have identified an
increase in ROS production during diabetes mellitus, and as a result, alleviating the
increased oxidative environment could serve as a potential therapeutic treatment for
diabetes mellitus.
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1.3 Mouse models of diabetic cardiomyopathy

The mechanisms underlying human diabetic cardiomyopathy are still only partly
understood. In order to understand diabetic cardiomyopathy more completely, both type
1 and type 2 rodent models have been used. Even though both type 1 and type 2
models show increased fatty acid utilization, decreased glucose utilization, and
mitochondrial dysfunction (29), differences also exist between the two phenotypes. For
example, increased ROS production in the hearts of type 2 diabetic models have been
determined (28, 77), as well as fatty acid-mediated mitochondrial uncoupling induced by
an increase in fatty acids (24, 28). Regardless of the overall similarities and differences
between the groups, each model has helped to advance our understanding of the
progression of diabetic cardiomyopathy.

Much of the research conducted in this area has employed mouse models, due
to their inability to develop atherosclerosis (unless modified to do so). Our laboratory
utilizes the type 1 diabetic STZ mouse model. STZ is a glucosamine-nitrosourea
antibiotic that is structurally similar to glucose and is taken into pancreatic β-cells by the
GLUT2 receptor. Through an ROS-mediated mechanism, STZ damages the pancreatic
β-cell from which insulin cannot then be produced (145). Studies use both high dose
and low dose STZ to render models type 1 diabetic. Our laboratory follows the protocol
of the Animal Models of Diabetic Complications Consortium using multiple low-dose (50
mg/kg body weight STZ dissolved in sodium citrate buffer) STZ injected intraperitoneally
over five consecutive days. This model was chosen because it is most widely used and
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does not induce deleterious effects associated with diabetes mellitus (165). Using this
method, cardiac dysfunction has been observed by decreased rates of relaxation,
contraction, developed pressure and systolic pressure (48, 90, 155) compared to
controls. The increased levels of ROS and superoxide production affect the antioxidant
capacity in the mitochondria, rendering mitochondria dysfunctional in the STZ model
(48, 67, 140). Studies have identified an increase in fatty acid oxidation, along with lipid
storage, while glucose oxidation is decreased in the STZ model (37, 61, 84). Calcium
handling is also decreased in the STZ model; consequently impacting cardiac function
(42, 62, 76).

Alloxan is another chemical used to induce type 1 diabetes mellitus. Alloxan
produces superoxide radials that eventually form ROS, which disrupts pancreatic β-cells
and subsequently prevents insulin production (145). One study using alloxan-induced
type 1 diabetic mice reported insulin secretory impairment in response to glucose (7).
Turko et al. (149) found a common nitrating species that may underlie the nitration
involved in mitochondria dysfunction in alloxan-susceptible mice. Aasum et al. also
observed decreased systolic and diastolic function (1).

Other type 1 diabetic models include the OVE26 mouse, the Akita mouse, the
non-obese diabetic (NOD) mouse, and the BioBreeding (BB) rat. The OVE26 mouse
was developed in 1989 by Epstein et al. (56) and was reported to have decreased
cardiac contractility and mitochondrial function, along with increased oxidative stress
(137, 138, 167). The Akita mouse, discovered in 1997 by Dr. Akio Koizumi (168), was
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reported to have increased mitochondrial content, even though overall mitochondrial
function was decreased (30, 31). First reported in 1980 (102) NOD mice have a
susceptibility to spontaneously develop type 1 diabetes mellitus (93). This model
appears to be used more for immunological responses on the development of diabetes
(55, 95). The BB rat is a model of human type 1 diabetes mellitus, from which two
inbred lines have been created: one that is prone to diabetes and the other is diabetic
resistant (160). The diabetic prone BB develops type 1 diabetes mellitus within 2 to 3
months. The diabetic resistant needs to be virally infected in order to develop diabetes
(88). Interestingly, Rodrigues and McNeill observed cardiac dysfunction in perfused
hearts from diabetic-prone BB rats, similar to the dysfunction observed in STZ rats and
the human population (126).

Rodent models of type 2 diabetes include the ob/ob mouse, the db/db mouse,
and the Zucker diabetic fatty rat. Both the ob/ob and db/db mouse were derived by
targeting the same mechanism. The ob/ob mouse resulted from a mutation in the leptin
gene (172), where as the db/db is a consequence of an impaired leptin receptor (44).
The ob/ob mouse develops type 2 diabetes by 15 weeks, even though they display
higher insulin levels and lower glucose tolerance by only 5 weeks (27). Compared to the
ob/ob, the db/db mouse is has a normal glucose tolerance at 4 weeks, but develops
type 2 diabetes at 8 weeks (27). Due to the earlier manifestation of type 2 diabetes, the
db/db mouse has greater contractile abnormalities (170). In both models, fatty acid
oxidation rates and oxidative stress levels are increased, while glucose oxidation rates
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are decreased (17, 24, 27, 29, 99, 103, 170). Mitochondrial dysfunction is also evident
in both models (23, 24).

The Zucker diabetic fatty rat, like the db/db, contains a mutation in the leptin
receptor, which is the cause of type 2 diabetes mellitus. Hyperglycemia develops
around 6 weeks of age; however, the high blood glucose levels are not stable until 10 12 weeks, when the insulin levels start to fall (29). The Zucker diabetic fatty rat has not
been studied as extensively as the mouse type 2 diabetic models. Even though cardiac
size is increased in this model (29), cardiac function is decreased (117, 169). The
decreased contractile function could be contributed to the increase in fatty acid
availability, which would also increase fatty acid oxidation (169). Carbohydrate oxidation
is also seen to decrease during the type 2 diabetic state (38).

1.4 Mitochondrial Subpopulations

Two distinct mitochondrial subpopulations are present in striated muscle:
subsarcolemmal (SSM) and interfibrillar mitochondria (IFM) (48, 116, 124) (Figure 1.1).
Each population is spatially, morphologically and functionally distinct. The SSM are
located just beneath the sarcolemma and produce primarily operate to actively transport
electrolytes and metabolites across the sarcolemma. They are larger in size and contain
lamelliform cristae (124). The IFM are situated between the myofibrils, are smaller,
more compact in size. Their cristae are lamelliform and tubular in shape, allowing for a
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higher concentration of protons, and subsequently, higher ATP synthase activity (124).
Compared to the SSM, the IFM have higher membrane potential and state 3 respiration
rates, as well as increased ATP production (157, 163). Their main function is suggested
to be to generate ATP for muscle contraction (48).

Figure 1.1. Mitochondrial subpopulations.
Electron micrograph of the placement of
subsarcolemmal mitochondria (SSM) and
interfibrillar mitochondria (IFM) in the heart
muscle (in situ) (79).

Literature has suggested that the two mitochondrial pools respond differently to
pathological insults, such as ischemia/reperfusion, aging, heart failure and diabetes (39,
47, 48, 80, 97, 123, 130). Chen et al. reported decreased mitochondrial respiration
through cytochrome oxidase, as well as increased hydrogen peroxide production from
electron transport chain (ETC) complexes I and III in both SSM and IFM after an
ischemic insult (39). Although, Lesnefsky et al. also reported an ischemia-mediated
mitochondrial respiration decrease through cytochrome oxidase, the SSM were the only
subpopulation affected (97). Aging also greatly impacts mitochondrial function. In 2002,
Hoppel et al. (80) reported decreased oxidative phosphorylation through ETC complex
III and IV, specifically in the IFM, of aged rats compared to control (80). Rosca et al.
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reported increased ETC complex I and complex III in the SSM, with no change in ETC
complex IV in canine coronary heart failure model as measured by Native PAGE (130).
Type 1 and type 2 diabetes mellitus affect the mitochondrial subpopulations.
Interestingly, type 1 diabetes mellitus has been shown to affect the IFM (48), whereas
type 2 diabetes affects the SSM (47, 123). Although the presence of hyperglycemia
leads to the phenotype of both type 1 and type 2 diabetes mellitus, it is unclear as to
why mitochondrial subpopulations are differentially affected. It has been suggested that
the spatial arrangement and environment of the distinct subpopulations allow for the
mitochondria to be impacted differently in response to pathological insults. For example,
type 2 diabetes mellitus is characterized by high levels of triglyceride accumulation and
lipid deposition (110), which could be the potential mechanism contributing to the
dysfunctional SSM, when compared to IFM during a type 2 diabetic insult, because of
the sub-sarcolemmal location of the SSM (110).

1.5 Mitochondrial dysfunction in the diabetic heart

Hyperglycemia is a recognized complication of both type 1 and type 2 diabetes
(132) and in combination with oxidative stress and subsequent increased production of
ROS, deleterious effects cause the heart and the organelles that reside within, such as
mitochondria, to become dysfunctional (125, 128, 138). Mitochondria are the main
source of ROS in cells and the effects of ROS damage have been linked to different
pathologies, such as ischemia/reperfusion injury, atherosclerosis, and diabetes mellitus
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(52, 115). Literature suggests that the increase in ROS production is the unifying
mechanism underlying mitochondrial dysfunction during both type 1 and type 2 diabetes
mellitus (26).

1.5.1 Mitochondrial oxidative stress

Mitochondria are more vulnerable to oxidative stress than other organelle
because the inner mitochondrial membrane (156) is the primary source of ROS
production, specifically at ETC complex I and complex III (115). ROS are suggested to
induce lipid modifications, DNA damage and protein damage (153). Along with the
elevated levels of free fatty acids observed during diabetes mellitus, lipid peroxidation
and membrane disruption are more likely to occur (53, 68) given the increase in ROS
production. Our laboratory reported increased damage to proteins and lipids, as
determined by nitrotyrosine content and lipid peroxidation in type 1 diabetic IFM,
respectively (48). Interestingly, animal models manipulated to overexpress players
involved in the antioxidant defense system, such as manganese superoxide dismutase
and mitochondrial phospholipid hydroperoxide glutathione peroxidase, have provided
protection against mitochondrial dysfunction associated with diabetes mellitus (15, 137).

1.5.2 Calcium homeostasis

The uptake of calcium into mitochondria regulates mitochondrial metabolism (54)
and acts to stimulate oxidative phosphorylation (13, 49, 74, 104). When needed, the
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calcium influx is increased enhancing ATP production in order to meet the ATP demand
needed to increase contractile force. In the presence of a pathological stimulus, calcium
entering mitochondria increases ROS by increasing oxidative phosphorylation.
Alteration in calcium homeostasis can also activate the opening of the mitochondrial
permeability transition pore (mPTP) and subsequently trigger apoptosis (25). One study
using type 1 diabetic rats, reported decreased calcium uptake, along with increased
mPTP opening (113). In agreement, our laboratory observed increased mPTP opening
in the IFM of type 1 diabetic mouse hearts (162). In conjunction with the increased
mPTP opening, an observed increase in cytochrome c release suggested damage to
the anchoring phospholipid environment, also an effect of increased ROS generation.

1.5.3 Lipotoxicity

Obesity associated with diabetes mellitus is linked to excess lipid deposition in
multiple tissues, including the heart (159). The tissues can store some of the lipid
deposition as triglycerides; however, the excess lipid deposition can cause lipotoxic
effects, affecting multiple processes. For example, the excess lipids are forced through
the oxidative machinery, causing mitochondrial dysfunction (166) and cardiac
dysfunction (78).

In regards to mitochondrial dysfunction, augmented lipid accumulation increases
mitochondrial fatty acid oxidation, which in turn alters different pathways that all lead to
cardiac contractile dysfunction. Literature has reported reduced ATP generation in the
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presence of increased fatty acid oxidation indicative of mitochondrial uncoupling (23).
Further, an increase in fatty acid oxidation is associated with increased ROS production
(154), which then oxidizes lipids contributing to mitochondrial and cardiac dysfunction.

1.5.4 Mitochondrial dysfunction in the type 1 diabetic heart

Even though mitochondrial dysfunction in the type 1 diabetic heart has been
identified, the mechanisms underlying the dysfunction are still being evaluated.
Mitochondrial respiration has been reported to be decreased during type 1 diabetes
mellitus using different substrates (48, 96, 152). Proteomic alterations have been
identified in the type 1 diabetic heart, with IFM being affected to a greater extent than
SSM (16). We and others have shown a decrease in ETC function during a type 1
diabetic insult, specifically in IFM (48, 96). ROS production has been shown to be
increased in type 1 OVE26 mice (142), as well as an increase in apoptotic susceptibility,
specifically in the IFM (162), all of which contributing to the observed mitochondrial
dysfunction.

1.5.5 Mitochondrial dysfunction in the type 2 diabetic heart

Many of the same characteristics of mitochondrial dysfunction reported from type
1 animal models are also reported from type 2 animal models; however, the diabetic
phenotypes between the two types include important differences. It is interesting to
point out that much of the mitochondrial dysfunction occurs in the SSM to a greater
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extent than the IFM during a type 2 diabetic insult, which is in contrast to type 1
diabetes mellitus. Obesity is associated with type 2 diabetes mellitus; therefore,
increases in lipid deposition cause much of the dysfunction during type 2 diabetes.
Mitochondrial respiration was reported to be decreased in the presence of both
glutamate and palmitoylcarnitine in a type 2 diabetic animal model, specifically in the
SSM (47). This finding is supported by total mitochondria isolated from human atrial
tissues, from which mitochondrial respiration in the presence of palmitoylcarnitine is
also decreased (9). The increased lipid deposition leads to increased lipid peroxidation
and subsequent ROS production. Further contributing to mitochondrial dysfunction
associated with type 2 diabetes mellitus is the proteomic alterations observed in the
diabetic SSM, of which many are involved in mitochondrial processes that are housed in
the IMM (156).

1.6 Inner Mitochondrial Membrane

A critical component of the mitochondrion is the IMM (156) (Figure 1.2), which is
composed of a specific lipid environment that houses many proteins required for proper
mitochondrial function. This membrane is the primary source of ROS generation,
making the IMM susceptible to oxidative damage. Subsequently, the integrity of the lipid
environment of the IMM is altered due to the increase in ROS and oxidative damage,
further enhancing mitochondrial dysfunction (159). The increased ROS target the lipids
of the IMM due to their highly unsaturated structure, causing enhanced lipid
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peroxidation (85) leading to disassociation of lipids and critical proteins that reside in the
IMM, such as the ETC complexes (2). During type 1 diabetes mellitus, ETC proteins
are decreased (16) along with their associated activities (48).

Figure 1.2. Schematic of the inner mitochondrial membrane. PE = Phosphatidylethanolamine; PI = Phosphatidylinositol; LPE = Lyso-phosphatidylethanolamine; VDAC
= voltage dependent anion channel; and ANT = adenine nucleotide transporter.

1.6.1 Inner mitochondrial membrane machinery

The IMM houses many proteins required for proper mitochondrial function,
including the machinery that produces ATP, ETC complexes, and protein import
machinery (Figure 1.2). Proteomic data has revealed that the IMM contains the highest
percentage of proteins affected by a diabetic insult (16). During a type 1 insult, IFM
proteins are affected to a greater extent compared to SSM proteins. Many of these
altered proteins are also affected during a type 2 diabetic insult, with the SSM being
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affected to a greater extent (47). An example of this phenomenon would be glucose
regulated protein 75 (Grp75), which is a key constituent in the protein import process.

Also housed in the IMM are the constituents involved in mitochondrial-mediated
apoptosis, such as the cytochrome c anchoring mechanism and adenine nucleotide
transporter, which forms a pore with voltage dependent anion channel to release
cytochrome c. The release of cytochrome c occurs when the anchoring lipids are
damaged during a pathological insult, in this case, diabetes mellitus. The phospholipid
environment is critical for the associated proteins to function properly. The impaired
mitochondrial function reported during a diabetic insult can be partially explained by
examining the IMM phospholipid environment, which contains a unique phospholipid,
cardiolipin.

1.6.2 Cardiolipin and the Biosynthesis Pathway

Cardiolipin is thought to play a key role in mitochondrial structure and
bioenergetics (2). Most abundant in the mammalian heart, cardiolipin is primarily located
in the IMM (133); however, literature suggests the presence of cardiolipin in the outer
mitochondrial membrane (50, 83). Cardiolipin is a unique phospholipid with a dimeric
structure containing three glycerol backbones and four fatty acyl side chains (133)
(Figure 1.3).
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Figure 1.3. Structure of tetralinoleoyl cardiolipin. Adapted from (94)

The biosynthetic pathway of cardiolipin starts in the outer mitochondrial
membrane

where

phosphatidic

acid

is

converted

into

cytidine

diphosphate

diacylglycerol (CDP-DAG) by cytidine diphosphate diacylglycerol synthase (CDS).
Phosphatidylglycerol synthase (PGS) then converts CDP-DAG to phosphatidyl-glycerol
phosphate (PG-P), where the phosphate is removed by phosphatidyl-glycerol
phosphatase (PGP), resulting in the formation of phosphatidylglycerol (PG). Cardiolipin
synthase (CRLS) catalyzes the condensation of CDP-DAG with PG, resulting in a
nascent form of cardiolipin (41, 101). Because the substrates used to make cardiolipin
do not contain the precise fatty acyl side chains for the specific tissue, a remodeling
process takes place converting the nascent form of cardiolipin to the mature form
containing specific fatty acyl side chains (41) (Figure 1.4).
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Figure 1.4. Cardiolipin biosynthetic pathway. Schematic illustrating cardiolipin
synthesis. PLA2= phospholipase A2; MLCL= monolyso-cardiolipin; TAZ= Tafazzin. Refer
to text for other abbreviations.

Depending on the tissue and environment, the side chains of cardiolipin are
composed of different fatty acids. Linoleic acid is the most abundant fatty acid side
chain found to compose the mature form of cardiolipin in cardiac mitochondria,
constituting about 80% of all cardiolipin (3, 133) (Figure 1.3). Each side chain of a tetralinoleoyl cardiolipin contains eighteen carbons with two double bonds, with the double
bonds serving as targets for ROS and oxidative damage (82, 85). The side chains of
cardiolipin create a conical shaped lipid (82), allowing it to interact with IMM proteins
and facilitate proper mitochondrial function.

Cardiolipin has been suggested to be involved in protein import (82, 148),
membrane stability (133), and cytochrome c attachment (85, 119). Other proteins that
rely on cardiolipin for proper function and activity are carriers of the IMM, such as
adenine nucleotide translocator (20), and

carnitine (86), pyruvate and phosphate

carriers (89, 107). Literature suggests an interaction between cardiolipin and the ETC
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complexes involved in oxidative phosphorylation (133), such as ETC complex I, III, IV,
and ATP synthase (63, 135).

This important lipid has been shown to play a critical role in the organization of
mammalian mitochondrial ATP synthase. It has been suggested that the IMM-bound F0
complex of ATP synthase contains high affinity binding sites for cardiolipin (2); however,
these specific binding sites are unknown. Cardiolipin is also known to trap protons
within its polar head group, serving as a proton reservoir to maintain IMM potential and
to contribute to ATP synthesis (72). Shotgun lipidomics have revealed decreased tetralinoleic cardiolipin content in diabetic mouse hearts and the authors have suggested a
possible mechanistic reliance on the interaction between IMM protein activity and
cardiolipin (73).

1.7 Protein Import

There are over 1500 proteins in the human mitochondria, of which only 13 are
transcribed and translated in the organelle (10, 32). The remaining 99% of the nuclear
encoded mitochondrial proteins need to be imported into the mitochondria through a
complex process. Proteomic analyses indicate a decreased abundance of nuclear
encoded proteins during a diabetic insult, which included proteins essential for proper
mitochondrial import processes (46, 150).
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Figure 1.5. Mitochondrial import of matrix-targeted proteins. Schematic
illustrating the protein import process (92).

Protein import is mutli-step, complex pathway from which nuclear-encoded
proteins enter the mitochondria (Figure 1.5). The constituents involved in this process,
outer membrane translocases (Tom), inner membrane translocases (Tim), and the
presquence translocase-associated motor (PAM), create a supercomplex that facilitates
the movement of proteins into the matrix (36). The protein import process begins
outside of the mitochondrion, where N-terminal pre-proteins are recognized by outer
mitochondrial membrane receptors Tom20 and Tom22. The pre-proteins then pass
through Tom40 and enter the inner mitochondrial space. Proteins that are targeted for
the matrix will then bind to the main IMM protein import pore, Tim23, with the help of
Tim21 and Tim50. Tim50 recruits the PAM complex, which pulls the pre-protein into the
matrix. The key constituent of the PAM complex, Grp75, also known as mortalin or
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mitochondrial heat shock protein 70 (mthsp70), binds to Tim44 on the matrix side and
through an energy-driven mechanism, diassociates from Tim44, pulling the pre-protein
completely into the matrix (156). Matrix-processing peptidase (MPP) cleaves the
targeting sequence from the pre-protein. The protein is then properly hsp60 and hsp10,
resulting in a mature protein in the mitochondrial matrix (35, 71, 92, 108, 139).
Depending on the N-terminal presequence, the protein can be targeted for either the
matrix, IMM, outer mitochonrial membrane or inter mitochondrial membrane space.

Mitochondrial protein import has been shown to be decreased in a type 1 diabetic
setting, specifically in the IFM (15). By using a novel mitochondrial protein import assay,
protein import rates into mitochodria can be measured (15). Figure 1.6A is a vector
map that illustrates the MitoGFP plasmid that is grown in a cell-free bacterial protein
lysate system. When the lysate is incubated with mitochondria in the presence of
substrates necessary for the import process to occur, protein import of MitoGFP1 is
initiated. Following a 10 minute incubation period, import is stopped and after
processing the mitochondria, a Western blot is performed to determine the amount of
MitoGFP1 that has been imported into the mitochondria. Figure 1.6B illustrates the
resulting Western blot probed for MitoGFP1, with lane 1 representing mitochondria
without the lysate, lane 2 depicting the lysate without mitochondria, whereas lane 3
demonstrates the presence of MitoGFP1 when mitochondria and the lysate are
incubated together. The top band, measured at 31 kDa, respresents the unprocessed
mitoGFP1 that has not yet been imported into the mitochondria. The bottom band,
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measured at 28 kDa, respresents the processed mitoGFP1that has been imported into
the mitochondria.

A.

B.

Mito

Lysate

Mito +
Lysate

1

2

3

31 kD
27 kD

Figure 1.6. MitoGFP1 construct and protein import. (A.) pMITOGFP1 plasmid. (B.)
Western blot of MitoGFP1 protein import into isolated cardiac mitochondria probed for
MitoGFP1 in samples containing mitochondria only (lane 1), MitoGFP1 protein lysate
(lane 2), or combined mitochondria and lysate (lane 3). Upper 31 kD band represents
the full length precursor MitoGFP1 un- processed; lower 27 kD band represents mature
cleaved MitoGFP1 protein residing within the mitochondrial matrix.

Baseler et al. previously reported protein import deficiency in type 1 diabetic
mice, specifically in the IFM (16). The deficiency was attributed to decreased Grp75
protein content in the diabetic IFM compared to control, with no observed differences in
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the SSM regarding protein import or Grp75 protein content (16). To date, protein import
has not been reported in a type 2 diabetic mouse model, nor in a diabetic human model.

1.8 Summary

In the United States, heart failure is the leading cause of mortality in patients with
DM (66). In 2010, 11.3% of the U.S. population age 20 and older suffered from diabetes
(43) and each year, approximately 15,000 more people over the age of 20 are
diagnosed with type 1 diabetes (127). Cardiovascular complications that arise from
diabetes mellitus, such as diabetic cardiomyopathy, are becoming a more prevalent tool
used for the diagnosis of heart failure; however, possible mechanisms involving
mitochondrial dysfunction associated with diabetic cardiomyopathy need to be further
examined to advance our understanding of the disease and its development. The goal
of this dissertation was to evaluate the impact of type 1 diabetes mellitus on the IMM
phospholipid environment, specifically cardiolipin, and the processes that are housed
within. Further, the mitochondrial dysfunction in the type 2 diabetic human heart was
examined with the intention of discovering potential targets for future therapeutic
strategies.
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ABSTRACT
Aims: We have previously reported alterations in cardiolipin content and inner
mitochondrial membrane (IMM) proteomic make-up specifically in interfibrillar
mitochondria (IFM) in the type 1 diabetic heart; however, the mechanism underlying this
alteration is unknown. The goal of this study was to determine how the cardiolipin
biosynthetic pathway and cardiolipin-IMM protein interactions are impacted by type 1
diabetes mellitus.
Main methods: Male FVB mice were made diabetic by multiple low-dose streptozotocin
injections and sacrificed five weeks post-diabetic onset. Messenger RNA was measured
and cardiac mitochondrial subpopulations were isolated. Further mitochondrial
functional experimentation included evaluating the protein expression of the enzymes
directly responsible for cardiolipin biosynthesis, as well as ATP synthase activity.
Interactions between cardiolipin and ATP synthase subunits were also examined.
Key findings: Western blot analysis revealed a significant decrease of cardiolipin
synthase (CRLS) protein content in diabetic IFM, with a concomitant decrease in its
activity. ATP synthase activity was also significantly decreased. We identified two novel
direct interactions between two subunits of the ATP synthase F0 complex (ATP5F1 and
ATP5H), both of which were significantly decreased in diabetic IFM.
Significance: Overall, these results indicate that type 1 diabetes mellitus negatively
impacts the cardiolipin biosynthetic pathway specifically at CRLS, contributing to
decreased cardiolipin content and loss of interactions with key ATP synthase F 0
complex constituents in the IFM.
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INTRODUCTION

Cardiovascular complications are the primary cause of morbidity in diabetic
patients, of which diabetic cardiomyopathy has been associated with mitochondrial
dysfunction (10, 28, 31). The inner mitochondria membrane (IMM) houses vital
processes in a specific lipid environment. Alteration in the IMM lipid environment has
been associated with dysfunction to mitochondrial processes (1, 6, 14, 18). Proteomic
analyses of type 1 diabetic mitochondria indicates that IMM proteins may be particularly
prone to damage and loss (3).

Impaired mitochondrial function, particularly in those processes situated in the
IMM, may be associated with disruption to the phospholipid environment contained
within. Most abundant in the mammalian heart, cardiolipin is a unique phospholipid,
primarily located in the IMM (26) and is thought to play a critical role in mitochondrial
structure and bioenergetics (1). The biosynthetic pathway (Figure 2.1) begins in the
outer mitochondrial membrane where phosphatidic acid is converted into cytidine
diphosphate diacylglycerol (CDP-DAG) by cytidine diphosphate diacylglycerol synthase
(CDS) (17). Phosphatidylglycerol synthase (PGS) then converts CDP-DAG to
phosphatidylglycerol phosphate (PG-P), where the phosphate is removed by
phosphatidylglycerol
phosphatidylglycerol

phosphatase
(PG).

(PGP),

Cardiolipin

resulting

synthase

in

the

formation

of

(CRLS)

then

catalyzes

the

condensation of CDP-DAG and PG, resulting in a nascent form of cardiolipin (6, 21).
Because the nascent cardiolipin does not contain the precise fatty acyl side chains for
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the specific tissue, a remodeling process takes place, where tafazzin (TAZ) or
monolysocardiolipin acyltransferase, converts the nascent cardiolipin to mature
cardiolipin containing specific fatty acyl side chains (6), which is dependent upon the
tissue and environment. Linoleic acid, the most abundant fatty acid found in cardiac
mitochondria, constitutes approximately 80% of all side chains (2, 26). The properties of
cardiolipin allow it to interact with IMM proteins and facilitate proper mitochondrial
function.

Literature suggests an interaction between cardiolipin and the electron transport
chain (ETC) complexes involved in oxidative phosphorylation (26), including complexes
I, III, IV, and ATP synthase (12, 27). Cardiolipin plays a critical role in the organization of
mammalian mitochondrial ATP synthase and it has been suggested that the F 0 complex
of ATP synthase contains high affinity binding sites for cardiolipin (1); however, the
specific binding sites remain undefined. Cardiolipin also serves as a proton reservoir for
maintenance of IMM potential thus, contributing to ATP synthesis (13). Shotgun
lipidomics revealed decreased tetralinoleic cardiolipin content in diabetic hearts
suggesting a possible mechanistic reliance on the interaction between IMM protein
activity and cardiolipin (14). We have previously reported decreased ETC protein
content and function in IFM following a type 1 diabetic insult (3, 8), correlating with
decreased tetralinoleic cardiolipin content, with no effect on subsarcolemmal
mitochondria (SSM) situated beneath the plasma membrane (8).
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To date, the impact of type 1 diabetes mellitus on the cardiolipin biosynthetic
pathway in mitochondrial subpopulations and on the interactions between cardiolipin
and IMM proteins has not been studied. We hypothesized that the decreased cardiolipin
content associated with type 1 diabetes mellitus results from defective cardiolipin
biosynthesis influencing its association with IMM proteins, with the effects being most
pronounced in IFM.
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MATERIALS AND METHODS

Experimental animals and induction of diabetes
The animal experiments in this study conformed to the National Institutes of
Health (NIH) Guidelines for the Care and Use of Laboratory Animals and were approved
by the West Virginia University Animal Care and Use Committee. Male FVB mice were
housed in the West Virginia University Health Sciences Center animal facility on a 12hr light/dark cycle in a temperature controlled room. Mice were given unlimited access
to a standard rodent diet and water. Type 1 diabetes mellitus was induced in 6-week-old
mice following the protocol of the Animal Models of Diabetic Complications Consortium
using multiple low-dose streptozotocin (STZ; Sigma-Aldrich Corporation, St. Louis, MO)
intraperitoneal injections. The STZ-induced type 1 diabetic model was chosen because
it is the most widely utilized model and the multiple low dose administration is not
associated with many of the deleterious side effects observed with the single high-dose
approach (34). Injections of 50 mg/kg body weight STZ dissolved in sodium citrate
buffer (pH 4.5) were performed daily for 5 consecutive days after 6 hours of fasting.
Mice serving as vehicle controls were given the same volume per body weight of
sodium citrate buffer. One week post-injection, hyperglycemia was confirmed by
measuring blood glucose (Contour Blood Glucose test strips; Bayer, Mishawaka, IN),
where > 250 mg/dL was considered diabetic. Five weeks after the onset of
hyperglycemia, animals were sacrificed for experimentation. Blood glucose levels were
again tested at this time and all remained > 250 mg/dL.
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Individual Mitochondrial Subpopulations Isolation
Five weeks post-diabetic onset, FVB mice and their littermate controls were
sacrificed and hearts excised. Hearts were rinsed in phosphate buffered saline (PBS,
pH 7.4), then blotted dry. SSM and IFM were isolated as previously described by
Palmer et al. (25) with modifications by our laboratory (8, 9, 33). Mitochondrial pellets
were resuspended in either KME buffer (100 mM KCl, 50 mM MOPS, and 0.5 mM
EDTA) for Western blot analysis and activity measurements, or in 1.0% NP-40
wash/binding buffer (10 mM HEPES (pH 7.4), 1.0% NP-40, 150 mM NaCl) for
cardiolipin/protein interactions. Protein content was determined by the Bradford method
using bovine serum albumin as a standard (4).

Cardiolipin
Isolated mitochondrial subpopulations from control and diabetic hearts were
pooled, and sent off to Avanti Polar Lipids, Inc. (Alabaster, AL) for cardiolipin analysis.
Extraction and analysis of cardiolipin species were based on the protocols of Sparagna
et al. (29) and Minkler et al. (23). In brief, cardiolipin detection was performed by liquid
chromatography (Dionex U-3000 binary HPLC) / hybrid tandem mass spectrometry
using a quadrapole -linear ion trap (API 4000 Qtrap) operated in the negative ion mode.
Mass spectrometer instrument conditions included a spray voltage of -4.5 kV, capillary
voltage of -150 V, heated capillary temperature of 400°C, and a sheath gas flow rate of
10 arbitrary units. Mitochondrial cardiolipin and internal standard spectra were identified
by multiple reaction monitoring. All experiments were performed in triplicate.
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mRNA Isolation and analysis
mRNA levels were examined as previously described (3). Briefly, hearts were
rinsed in phosphate buffered saline (PBS, pH 7.4) then snap frozen in liquid nitrogen.
Thirty milligrams of tissue was excised from control and diabetic hearts from which the
mRNA was extracted using an RNeasy mini kit, per manufacturer’s instructions
(Qiagen, Valencia, CA) and reverse transcribed. Equal amounts of cDNA from the
hearts of control and diabetic mice were subjected to real-time PCR. Custom primers
were designed for target genes CDS, PGS, CRLS, and TAZ. SYBR Green I was used
for quantification of respective cDNA replicates (Qiagen, Velencia, CA). Data were
normalized by gene expression relative to the levels of GAPDH.

Western Blot Analyses
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was
run on a 4-12% gel as previously described (20, 33) with equal amounts of protein
loaded for each study treatment.

Relative amounts of subpopulation-specific CDS,

PGS, CRLS, and TAZ, were assessed using the following primary antibodies; anti-CDS
rabbit antibody (product No. ab84019, Abcam, Cambridge, MA), anti-PGS rabbit
antibody (product No. ab104815, Abcam, Cambridge, MA), anti-CRLS rabbit antibody
(product No. 49444_P050, Aviva Systems Biology, San Diego, CA), and anti-TAZ rabbit
antibody (product No. ab84927, Abcam, Cambridge, MA). The secondary antibody
used was a goat anti-rabbit IgG horseradish peroxidase conjugate (product No.
10004301, Cayman Chemical Company, Ann Arbor, MI).

Detection of signal was

performed according to the Pierce ECL Western Blotting Substrate detection system
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manufacturer’s directions (Thermo Fisher Scientific Inc., Rockford, IL). Cytochrome c
oxidase (COX IV) was used to control for protein loading (product No. ab16056, Abcam,
Cambridge, MA). Quantification of chemiluminescent signals were assessed using a
G:Box Bioimaging System (Syngene, Frederick, MD), and the data captured using
GeneSnap software (Syngene, Frederick, MD). Densitometry was measured using
Image J Software (National Institutes of Health, Bethesda, MD).

Cardiolipin Synthase (CRLS) Activity
CRLS activity was assessed as previously described
modifications. Briefly, a reaction mixture containing 20 μM

(5) with minor

14

C-oleoyl-CoA (50

mCi/mmol; American Radiolabeled Chemicals, Inc, MO), 2.0 mM LPG [1-oleoyl-2hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)]] and 2.0 mM CDP-DAG (Avanti Polar
Lipids Inc., Alabaster, AL) were incubated with 50 μg of lysed mitochondrial protein for
30 min at 37°C. The reactions were terminated by adding chloroform/methanol, followed
by a quick vortex, then chloroform, followed by a quick vortex and lastly, 0.1 M KCl to
facilitate phase separation. A brief centrifugation was performed to extract lipids. The
organic phase was collected, dried under an argon stream and separated by high
performance thin layer chromatography plates (Whatman, GE Healthcare, U.S.A) with
chloroform/hexane/methanol/acetic acid (25:15:5:2.5 by volume) as the developing
solvent. The high performance thin layer chromatography plates are then stained with
iodine vapor. The appropriate lipid spots are scraped off the plate and dissolved in
scintillation fluid for scintillation counting.
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ATP Synthase Activity
Activity was measured in control and diabetic mitochondrial subpopulations as
oligomycin-sensitive ATPase activity using an assay coupled with pyruvate kinase
which converts the ADP to ATP and produces pyruvate from phosphoenolpyruvate as
previously described (7). Protein content was assessed as described above (4) with
final values expressed as nanomoles of NADH per minute per milligram of protein,
equal to the nanomoles of NADH oxidized per minute per milligram of protein.

Lipid-Protein Interaction
Cardiolipin-coated

beads

(Product

No.

P-BCLP,

Echelon

Biosciences

Incorporated, Salt Lake City, UT) were used to determine protein interactions with
cardiolipin per the manufacturer’s instructions. In brief, 100 µl of cardiolipin-coated
beads were incubated with 600 µg mitochondrial protein diluted in 1.0% NP-40
wash/binding buffer overnight at 4°C. The beads were spun down at 800 x g. The
supernatant containing the unbound proteins was collected and the beads were washed
four times with 10x excess of wash/binding buffer. The proteins bound to the beads
were eluted with 4x Laemmli sample buffer and heated to 95°C. A Western blot was
then performed on the eluted protein from the beads and the unbound protein located in
the supernatant using the following specific antibodies: anti-ATP5F1 mouse antibody
(product No. ab117991, Abcam, Cambridge, MA), anti-ATP5H mouse antibody (product
No. ab110275, Abcam, Cambridge, MA), anti-ATPB mouse antibody (product No.
ab14730, Abcam, Cambridge, MA), anti-ATP5A (product No. ab110273, Abcam,
Cambridge, MA), and anti-GRP75 rabbit antibody (product No. 2816S, Cell Signaling
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Technology, Danvers, MA). The secondary antibodies used were either a goat antirabbit IgG horseradish peroxidase conjugate (product No. 10004301, Cayman Chemical
Company, Ann Arbor, MI) or a goat anti-mouse IgG horseradish peroxidase conjugate
(product No. 31430, Thermo Fisher Scientific Inc., Rockford, IL). Detection of signal was
performed according to the Pierce ECL Western Blotting Substrate detection system
manufacturer’s directions (Thermo Fisher Scientific Inc., Rockford, IL). Quantification of
chemiluminescent signals were assessed using a G:Box Bioimaging System (Syngene,
Frederick, MD), and the data captured using GeneSnap software (Syngene, Frederick,
MD) as above. Densitometry was measured using Image J Software (National Institutes
of Health, Bethesda, MD) as above. The association between cardiolipin and the
mitochondrial protein of interest was determined by using the densitometric ratio of the
protein bound to native cardiolipin/protein bound to native cardiolipin + protein bound to
the cardiolipin-coated beads.

Statistics
Means and SEMs were calculated for all data sets. Data were analyzed using a
Student’s t-test (GraphPad Software Inc., La Jolla, CA). Differences between control
and diabetic groups were considered statistically significant when a P < 0.05 was
observed.
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RESULTS

Cardiolipin Content in the Diabetic Heart
Han et al. (14) indicated an overall decrease in cardiolipin content in the diabetic
heart and our laboratory has previously reported decreased tetralinoleic cardiolipin
content in the diabetic IFM (8). Because CRLS synthesizes the nascent form of
cardiolipin, total cardiolipin content was measured. The cardiolipin content in the IFM
significantly decreased from 84.46 + 1.93 nmol/mg of protein in the control heart to
48.75 + 2.83 nmol/mg of protein in the diabetic heart, with no difference in the SSM
(44.99 + 1.75 nmol/mg of protein in control heart compared to 37.87 + 0.11 nmol/mg of
protein in diabetic heart); therefore, we hypothesized that the decrease in cardiolipin
may be caused by an alteration in the cardiolipin biosynthetic pathway during a diabetic
insult.

mRNA Analyses of Cardiolipin Biosynthesis Pathway Constituents
To gain insight into the impact of diabetes mellitus on transcriptional regulation of
the enzymatic components of the cardiolipin biosynthetic pathway, the mRNA levels of
three constituent enzymes, CDS, PGS, and CRLS, as well as the remodeling enzyme
TAZ, were analyzed. The results indicated no significant differences between control
and diabetic heart for any of the constituents responsible for cardiolipin biosynthesis or
remodeling (Table 2.1). These results suggest that the observed decreased in IFM
cardiolipin content resulting from a type 1 diabetic insult does not occur at the
transcriptional level.
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The expression levels of other IMM proteins were also listed in Table 1. None of
the mRNA levels of proteins involved in protein import were altered in a diabetic heart.
Of all the transcripts involved in oxidative phosphorylation, only electron transfer
flavoprotein-ubiquinone oxidoreductase was significantly decreased in the diabetic. This
protein is responsible for the transferring of electrons to the mitochondrial respiratory
chain. This decrease suggests a reduction in the electron flux through the respiratory
chain, which could potentially cause decreased oxidative phosphorylation. This potential
result is supported by decreased mitochondrial respiration in the presence of type 1
diabetes mellitus reported by our laboratory (Dabkowski et al. 2009).

Protein Analyses of Cardiolipin Biosynthesis Pathway Constituents
To determine the impact of diabetes mellitus on translational regulation of the
enzymatic components of the cardiolipin biosynthetic pathway, the protein levels of
three constituent enzymes, CDS, PGS, and CRLS, as well as the remodeling enzyme
TAZ, were analyzed. Western blot analyses revealed a significant decrease only in
CRLS protein content in diabetic IFM as compared to control, with no impact on CRLS
protein content in the SSM (Figures 2.2E and 2.2F). No significant differences were
observed in the protein levels of the other cardiolipin biosynthetic enzymes assessed,
regardless of subpopulation (Figure 2.2). It is important to note that CDS-2 is the major
isoform in the heart and when the protein expression was measured, there was no
difference between the two treatment groups for either subpopulation (data not shown).
These results indicate that the observed decrease in IFM cardiolipin content resulting
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from a type 1 diabetic insult is associated with a decrease in the protein content of
CRLS, and thus the biosynthetic pathway.

Enzymatic Activity Analyses of CRLS
Because CRLS protein content was the only change observed in the biosynthetic
pathway following a diabetic insult, we investigated the impact of diabetes mellitus on
CRLS enzymatic activity using an assay that utilizes
donor.

14

C-oleoyl-coenzyme A as an acyl

14

C-oleoyl-coenzyme A lipid was incubated with additional compounds and

mitochondrial protein then subjected to high performance thin layer chromatography.
Our results revealed a decrease in CRLS activity in diabetic IFM as compared to control
(Figure 2.3B), with no change in the SSM (Figure 2.3A). During high performance thin
layer chromatography, PG runs below cardiolipin, so as a control to ensure that the
assay was only affecting the radioactivity incorporated into cardiolipin, the amount of
radioactivity incorporated into PG was also measured through scintillation counting. The
results indicated no change in

14

C-PG in diabetic mitochondria relative to control for

either subpopulation (Figures 2.3C and 2.3D). These results complement the CRLS
proteomic data and suggest that loss of CRLS protein in the IFM results in a decrease
in CRLS enzymatic activity.

ATP Synthase Activity Analyses
Literature suggests that cardiolipin interacts with components of the ATP
synthase complex (1, 11); however, these interaction sites are unknown. Further,
previous proteomic data from our laboratory indicates that ATP synthase components
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are decreased in diabetic IFM (3). As a result, we determined whether the activity of the
ATP synthase complex was impacted in diabetic mitochondria. Our analyses indicated
that ATP synthase activity was significantly decreased in the diabetic IFM as compared
to control (Figure 2.4B) with no differences observed in the SSM subpopulation (Figure
2.4A). These results suggest that the decrease in ATP synthase activity observed in
diabetic IFM is associated with a decrease in cardiolipin content, which may be
influencing its functional properties.

Cardiolipin and ATP Synthase Interaction
To gain insight into which ATP synthase constituent proteins may be interacting
with cardiolipin, we developed an approach in which we incubated cardiolipin-coated
beads with mitochondrial proteins and probed for the interaction. Figure 2.5A and 2.5B
demonstrates direct association of cardiolipin with ATP synthase subunit b (ATP5F1)
and ATP synthase subunit d (ATP5H), both of which are subunits of the F0 complex, or
proton pore, of the ATP synthase. To validate that the cardiolipin-coated beads were
specifically binding to proteins that interact with cardiolipin, interactions of proteins not
associated with cardiolipin were examined. First, ATP synthase alpha (ATP5A) and ATP
synthase beta (ATPB) were measured. The results indicated that neither protein was
interacting with the cardiolipin-coated beads (Figures 2.5C and 2.5D, respectively).
Next, glucose regulated protein 75 (GRP75), a protein located in the mitochondrial
matrix, was examined. The results indicated the absence of GRP75 bound to the
cardiolipin-coated beads in both subpopulations (Figures 2.5E and 2.5F, respectively).
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Once the interactions between the aforementioned ATP synthase subunits and
cardiolipin were detected, we quantified the association between the lipid and protein
that occurs in the mitochondrion during a diabetic insult. By assessing proteins that are
associated with native cardiolipin, which are incapable of binding to the coated beads
(native bound), as well as those proteins that can bind to the beads (bead bound), we
were able to determine how diabetes mellitus impacts cardiolipin association with these
two proteins. Figure 2.6A represents the protein content of ATP5F1 in the different
mitochondrial subpopulations of control and diabetic hearts, respectively, while Figure
2.6B represents the protein content of ATP5H. In order to quantify the associations of
ATP synthase subunits and native cardiolipin, the optical density of the band that
resulted from the protein interacting with native cardiolipin (native bound protein) was
divided by the optical density of the bands that resulted from both the protein bound to
native cardiolipin (native bound) and the protein bound to the cardiolipin-coated beads
(bead bound). This ratio was used to quantify the interactions of cardiolipin with the
protein in control and diabetic mitochondrial subpopulations. The results indicated no
difference in the associations between cardiolipin and ATP5F1 or ATP5H in the diabetic
SSM compared to controls (Figures 2.6C and 2.6D, respectively). Interestingly, a
significant decrease in the interactions between native cardiolipin and both ATP5F1 and
ATP5H in diabetic IFM, as compared to control, was observed (Figures 2.6E and 2.6F,
respectively).
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DISCUSSION

Mitochondrial dysfunction is an underlying contributor to diabetic cardiomyopathy
(10, 28, 31). The IMM is an important submitochondrial locale which houses the
machinery required for a number of mitochondrial functional processes. When the lipid
environment of the IMM is altered, the processes contained within can become impaired
(1, 6, 14, 18). Cardiolipin, makes up approximately 20% of the total IMM phospholipid
membrane (32) and is required for proper functioning of a number of mitochondrial
processes (6, 12, 18). In this study, we observed a decrease in total cardiolipin content
in the diabetic IFM. Our laboratory has previously reported significant decreases in
tetralinoleic cardiolipin content of diabetic IFM, as well as loss of a number of proteins
that are constituents for crucial functional processes (3, 8). These results are further
supported by others who have reported decreased total cardiolipin content 28 days after
the induction of diabetes mellitus (14), as well as decreased tetralinoleic cardiolipin in
diabetic mouse hearts compared to control days after the induction of diabetes mellitus
(15). Thus, our hypothesis for the current study centered on understanding whether
proteomic loss of IMM constituents and cardiolipin content was the result of dysfunction
to the pathway responsible for cardiolipin synthesis. If our hypothesis were to be
supported, it would suggest a mechanism contributing to mitochondrial dysfunction in
the diabetic heart.

The biosynthesis of cardiolipin occurs in the IMM and is a multistep process
(Figure 2.1). To determine whether alterations in the cardiolipin biosynthetic pathway
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contribute to loss of cardiolipin, mRNA and protein levels for a number of key
constituents were measured. The results indicated no difference in mRNA levels
between control and diabetic hearts for any of the enzymes directly responsible for
cardiolipin biosynthesis; however, a significant decrease in CRLS protein content was
observed in the diabetic IFM. It is unclear why CRLS protein content was decreased
specifically in the IFM though the observation may be the result of decreased protein
import specifically in the diabetic IFM, which has been reported previously (3).

Because CRLS was the only enzyme affected by a type 1 diabetic insult, we
determined whether the response influenced the activity of the CRLS enzyme. Using
14

C-oleoyl-coenzyme A as an acyl donor, we measured incorporation of

14

C to assess

CRLS activity. One limitation to this method is that remodeling of cardiolipin is not taken
into account and other methods do not possess this limitation. Nie et al. (24) reported
that lysophosphatidylglycerol acyltransferase also acts as a CRLS, converting lyso-PG
to PG; therefore, to ensure the CRLS activity assay was only measuring the
incorporation of

14

C into cardiolipin, we measured the incorporation of

Results indicated no change in

14

C into PG.

14

C- PG levels between diabetic and control samples for

either subpopulation, and a significant decrease in

14

C-cardiolipin levels in diabetic IFM

compared to control, with no change in the SSM. These results instill confidence that
the methods utilized in our studies are reliable.

Though our data indicated decreased CRLS protein content and activity in the
diabetic IFM relative to control with no change observed in the SSM, the protein content
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of CRLS was not different between the SSM and IFM subpopulations; therefore, this
eliminated the possibility that absolute CRLS protein levels underlie the decreased
CRLS activity observed in the IFM. Hatch et al. (16) reported no change in PG or
cardiolipin biosynthesis during a 4 day or 28 day diabetic insult in rats and Taylor et al.
(30) suggested that neither cardiolipin content nor CRLS activity was altered during
STZ-induced diabetes. These results were obtained by examining total mitochondria as
opposed to our current study examining mitochondrial subpopulations, which may
explain the different results between studies. In either case, the results support the
importance of examining the two distinct pools of mitochondria.

Previous research has indicated an association between cardiolipin and ETC
complexes I, III and IV, from which the contact points with cardiolipin have been
identified (12, 27). Literature has also shown an association between cardiolipin and
ATP synthase (1, 11). One study demonstrated that cardiolipin is central for the
assembly of ATP synthase dimers, affecting the organization and ultimately the
structure of the IMM (1). Other studies have suggested that the interaction between
cardiolipin and the ATP synthase complex occurs on subunits composing the F0
complex of the ATP synthase due to its location within the IMM (11). Although an
association between cardiolipin and ATP synthase has been reported, the direct contact
points have not been identified. For this reason, we used a novel cardiolipin-coated
bead assay to separate out the two pools of specific ATP synthase subunits – those
already bound to native cardiolipin and those available to bind to the cardiolipin-coated
beads. The ATP synthase subunits predicted to interact with cardiolipin were identified
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using previous proteomic data performed in our laboratory (3). Western blot analysis
revealed two direct associations between cardiolipin and ATP synthase.

It is important to note that although the cardiolipin-bead pull-down assay is a
quick and accessible method to gather cardiolipin-protein interaction data, the assay
requires a large amount of protein. This is a limitation when measuring associations
within mitochondrial subpopulations, due to limited yields of mitochondrial subpopulation
protein content as compared to the analysis of total mitochondria. Nevertheless, we are
the first to detect direct associations between cardiolipin and two specific ATP synthase
subunits.

To gain insight into whether cardiolipin association with the identified ATP
synthase subunits was compromised in diabetic mitochondria, we performed analyses
in control and diabetic mitochondria. Western blot analysis revealed a lighter band when
measuring the association between specific ATP synthase subunits and native
cardiolipin (represented by the native bound lane) in the diabetic IFM compared to
control. This finding suggests that the association between the native form of cardiolipin
and the ATP synthase subunits is less in the diabetic IFM compared to control. Western
blot analysis also revealed a denser band when measuring the association between the
subunit and cardiolipin-coated beads (represented by the bead bound lane) in the
diabetic IFM compared to control. The denser band suggests that more ATP synthase
subunits are not in association with cardiolipin, but are free to bind to the cardiolipincoated beads in the diabetic IFM. Taken together, these results indicate that the
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decrease in interaction between native cardiolipin and ATP synthase could be an
underlying mechanism causing decreased ATP synthase activity in the diabetic IFM.

A number of studies have utilized cell lines to examine the physiological role of
cardiolipin. When the structural gene encoding CRLS was disrupted resulting in
depletion of cardiolipin in the mitochondrial membranes of Saccharomyces cerevisiae
cells, ATPase activities, cytochrome oxidase activities, membrane potential and protein
import were all decreased (18). This study concluded that cardiolipin is required for
maintaining mitochondrial function. Chen et al. (5) identified and characterized the
cDNA encoding human CRLS. The human CRLS was expressed in COS-7 cells from
which cardiolipin was not only efficiently synthesized in vitro using CDP-DAG and PG as
substrates, but was also synthesized at an increased rate. Kiebish et al. (19)
determined that CRLS overexpression in a STZ-induced diabetic model attenuated
mitochondrial dysfunction associated with diabetes mellitus. Although these authors did
not find a difference in total cardiolipin content between diabetic and control hearts, the
overexpression of CRLS increased cardiac cardiolipin remodeling and lipidomic flux,
which in turn, increased tetralinoleic cardiolipin. The novel finding of CRLS-mediated
regulatory control was central in the preservation of mitochondrial function during
diabetic insult. This study further supports the importance of IMM preservation.

Though our data suggest that changes in essential constituents in the cardiolipin
biosynthetic pathway (i.e., CRLS) are associated with a decrease in cardiolipin, it is
important to note that diabetes mellitus is a multifactorial disease that influences a
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number of processes, specifically in mitochondria. Increased content of the oxidized
form of cardiolipin in the diabetic IFM has been reported by our laboratory (Dabkowski
et al. 2009), thus one must consider that an oxidative stress pathway may also be
contributing to the results reported in this study. Increased oxidation of cardiolipin would
likely predispose the phospholipid to loss, influencing mitochondrial functionality (22).
Future studies in which manipulation of mitochondrial oxidative milieu specifically at the
IMM may lend insight into the contribution of oxidative stress.
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CONCLUSION
In conclusion, our results indicate the importance of preserving the IMM during
type 1 diabetes mellitus. We show dysregulation of the cardiolipin biosynthetic pathway
during a diabetic setting, as seen by a decrease in CRLS protein content and activity in
the diabetic IFM. These studies are the first to demonstrate a direct association
between cardiolipin and ATP synthase F0-complex subunit b and d in both mitochondrial
subpopulations. CRLS and IMM conservation represents a potential therapeutic target
that may be manipulated for treatment against development of cardiomyopathy
associated with the type 1 diabetic heart.
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Figure 2.1 Cardiolipin biosynthetic pathway. Schematic diagram illustrating
cardiolipin biosynthetic pathway.
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A.

SSM: CDS

B.

COXIV

C.

COXIV

SSM: PGS

D.

COXIV

E.

IFM: CDS

IFM: PGS
COXIV

SSM: CRLS

F.

COXIV

IFM: CRLS
COXIV

*

G.

SSM: TAZ

H.

COXIV

IFM: TAZ
COXIV

85

Figure 2.2 Protein content of cardiolipin biosynthetic pathway constituents.
Assessment of cardiolipin biosynthetic pathway constituents was performed by Western
blot using specific antibodies. (A) and (B): representative CDS content from SSM and
IFM control (n=7) and diabetic (n=8), respectively; (C) and (D): representative PGS
content from SSM (n=7 for each group) and IFM (n=8 for each group) control and
diabetic, respectively; (E) and (F): representative CRLS content from SSM and IFM
control (n=8) and diabetic (n=7), respectively; (G) and (H): representative TAZ content
from SSM and IFM control (n=7) and diabetic (n=7), respectively. Control for loading
was confirmed using COX IV probing. Values are expressed as means + SEM; *P< 0.05
for control vs. diabetic groups. Abbreviations: CDS = cytidine diphosphate diacylglycerol
synthase; PGS = phosphatidylglycerol synthase; CRLS = cardiolipin synthase; TAZ =
tafazzin; IFM = interfibrillar mitochondria; SSM = subsarcolemmal mitochondria.
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Figure 2.3
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IFM

Figure 2.3 Cardiolipin synthase (CRLS) activity. CRLS activity was assessed using a
14

C-acyl donor. (A): CRLS activity measured in SSM diabetic and control samples. (B):

CRLS activity measured in IFM diabetic samples compared to control samples. (C): PG
radioactive counts/minute/mg of protein measured in SSM diabetic samples compared
to control samples. (D): PG radioactive counts/minute/mg of protein measured in IFM
diabetic samples compared to control samples. Values are expressed as means+ SEM;
n=8 for each group. *P < 0.05 for control vs. diabetic groups. Abbreviations: CDS =
cytidine diphosphate diacylglycerol synthase; PG = phosphatidylglycerol; IFM =
interfibrillar mitochondria; SSM = subsarcolemmal mitochondria.
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Figure 2.4
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Figure 2.4 ATP synthase activity. Spectrophotometric analysis of ATP synthase
activities in control and diabetic samples. (A): ATP synthase activity from SSM control
and diabetic groups. (B): ATP synthase activity from IFM control and diabetic groups.
Values are expressed as means + SEM; n=4 for each group. *P< 0.05 for control vs.
diabetic groups. Abbreviations: IFM = interfibrillar mitochondria; SSM = subsarcolemmal
mitochondria.
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Figure 2.5
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Figure 2.5 Cardiolipin – ATP synthase association. Mitochondrial protein was
incubated with cardiolipin-coated beads. Western blots were performed to determine
associations between cardiolipin and (A): ATP synthase subunit b (ATP5F1); n=3 for
each group and (B): ATP synthase subunit d (ATPH); n=3 for each group (C): ATP
synthase alpha (ATP5A); n=2 for each group and (D): ATP synthase beta (ATPB); n=2
for each group and (E): Glucose regulated protein (GRP75) in the SSM; n=3 for each
group and (F): Glucose regulated protein (GRP75) in the IFM; n=3 for each group using
specific antibodies (Representative blots shown). Abbreviations: IFM = interfibrillar
mitochondria; SSM = subsarcolemmal mitochondria.
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Figure 2.6
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Figure 2.6 Native cardiolipin – ATP synthase association. The association between
cardiolipin and the detected interactions were measured in control and diabetic
mitochondrial subpopulations. (A): Representation of ATP5F1 protein content in control
and diabetic SSM and IFM, respectively. The “Bead bound” column represents ATP5F1
that was eluted off of the cardiolipin-coated beads, whereas the “Native bound” column
represents ATP5F1 associated with native cardiolipin that was present in the
supernatant. The “Total” band represents the total ATP5F1 protein content in isolated
mitochondria. (B): Representation of ATP5H in the same manner as ATP5F1 (Figure
2.6A). Quantification of the association between native cardiolipin and ATP5F1 in
control and diabetic hearts in (C): SSM and (E): IFM. Quantification of the association
between native cardiolipin and ATP5H in control and diabetic hearts in (D): SSM and
(F): IFM. Values are expressed as means + SEM; n=3 for each group. *P< 0.05 for
control vs. diabetic groups. Abbreviations: IFM = interfibrillar mitochondria; SSM =
subsarcolemmal mitochondria.
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Table 2.1
Diabetic vs.
Control

p-value

Cytidine diphosphate-diacylglycerol synthase 1

1.18

0.17

Phosphatidylglycerol synthase 1

0.92

0.47

Cardiolipin synthase

0.98

0.91

Tafazzin

0.86

0.24

Mitochondrial import inner membrane translocase subunit TIM16

0.98

0.89

Mitochondrial import inner membrane translocase subunit TIM14

0.97

0.98

NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial

0.91

0.20

NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial

1.05

0.60

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1

0.97

0.84

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2

0.98

0.92

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3

0.94

0.45

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4

0.95

0.63

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12

0.92

0.62

Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial

1.02

0.88

Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial

0.62

0.000049

Cytochrome b-c1 complex subunit 1, mitochondrial

1.06

0.49

Cytochrome b-c1 complex subunit Rieske, mitochondrial

0.96

0.69

Cytochrome c1, heme protein, mitochondrial

0.99

0.98

ATP synthase subunit b, mitochondrial

0.97

0.75

0.88

0.40

mRNA
Cardiolipin biosynthesis

Protein import

Oxidative phosphorylation

Miscellaneous
Prohibitin-2
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Table 2.1. mRNA analysis of inner mitochondrial membrane proteins. mRNA was
isolated from control and diabetic hearts. The mRNA content levels for inner
mitochondrial membrane proteins were assessed. Values are expressed as fold change
in diabetic heart as compared to control heart; n=4 for each group. The bold value
indicates a p-Value < 0.05 for diabetic vs. control hearts.
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ABSTRACT

Mitochondrial dysfunction is a central contributor to the development of diabetic
cardiomyopathy. The examination of mitochondrial function is further complicated by the
existence of two cardiac mitochondrial subpopulations, subsarcolemmal mitochondria
(SSM) and interfibrillar (IFM) mitochondria. We have previously reported decreased
SSM function in type 2 db/db mouse heart. Currently, subpopulation based
mitochondrial analyses have not been explored in type 2 diabetic human heart. The
goal of this study was to examine the impact of type 2 diabetic insult on mitochondrial
function in the human heart. Mitochondrial subpopulations were isolated from atrial
appendages of non-diabetic and diagnosed type 2 diabetic patients. Glucose-mediated
and fatty acid-mediated state 3 and state 4 respiration rates were decreased in diabetic
SSM as compared to non-diabetic SSM (P < 0.05 for both), with no change in IFM.
Electron transport chain complexes I and IV activities were decreased in diabetic SSM
compared to non-diabetic SSM (P < 0.05 for both), with a concomitant decrease in
complex I and IV protein content in diabetic SSM (P < 0.05 for both). The primary factor
accounting for mitochondrial function was diabetes mellitus, when compared to other
co-morbidities such as coronary artery disease and hypertension. Using spline models
to determine correlative risk for mitochondrial dysfunction indicated that diabetic
patients display the same level of state 3 and electron transport chain complex I
dysfunction regardless of absolute glycated hemoglobin (HbA1c) and blood glucose
levels. Overall, the results suggest that independent of other pathologies mitochondrial
dysfunction is present in the SSM of type 2 diabetic patients and identifies a threshold
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where mitochondrial dysfunction is present regardless of absolute HbA1c or blood
glucose levels.
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INTRODUCTION

Diabetes mellitus is a condition that is increasingly becoming an epidemic, with
an estimated 330 million affected worldwide by the year 2030 (10). Of the individuals
diagnosed with the disease, type 2 diabetes mellitus accounts for approximately 9095% of cases (10), and has been attributed to sedentary lifestyle (20). Type 2 diabetes
mellitus results from insulin resistance caused by an imbalance of the body’s glucose
homeostasis (20). The body does not properly use the insulin produced in response to
increased blood glucose levels; therefore, the pancreas eventually loses its ability to
produce insulin (10).

Cardiovascular complications are the leading cause of morbidity and mortality in
individuals with diabetes mellitus (17). Mitochondrial dysfunction has been shown to
contribute to the development of these cardiovascular complications during type 2
diabetes mellitus (7, 8, 13). In the cardiomyocyte, there are two mitochondrial
subpopulations that are morphologically, biochemically, and spatially distinct (15, 23).
The two separate pools of mitochondria respond differently in the face of a
cardiovascular insult, such as diabetes, aging, and ischemia/reperfusion (13, 14, 21,
22). The subsarcolemmal mitochondria (SSM) are located just beneath the
sarcolemma, whereas the interfibrillar mitochondria (IFM) are located in between the
myofibrils.
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Previously, examination in a type 2 diabetic db/db mouse model revealed cardiac
dysfunction (6, 28). When mitochondrial function was assessed, decreased respiration
rates and oxidative phosphorylation were observed (26). Upon examination of the two
separate pools of mitochondria, our laboratory observed decreased respiration and
oxidative phosphorylation, as well as an altered proteomic profile primarily in the
diabetic SSM, with the IFM being affected to a lesser extent (13).

Though animal studies have provided convincing evidence of differential
responses by spatially-distinct mitochondrial subpopulations during type 2 diabetic
insult, studies confirming these effects in a human patient population are limited.
Skeletal muscle biopsies have been revealed decreased mitochondrial function in
skeletal muscle of type 2 diabetic patients (19), specifically in the SSM subpopulation
(25). Fewer studies have examined the human heart due to the invasive procedure
required to obtain human heart tissue. Anderson et al. reported decreased
mitochondrial function in type 2 diabetic atria (3, 4). Nevertheless, it is still unclear as to
how diabetes mellitus affects mitochondrial subpopulations in the diabetic human heart.

The goal of this study was to determine how mitochondrial subpopulations are
affected in the heart of type 2 diabetic patients compared to non-diabetic patients. Our
results suggest that type 2 diabetes mellitus negatively impacts the SSM to a greater
extent than the IFM and that the observed dysfunction may be attributed to decreased
oxidative phosphorylation machinery. Our data also demonstrate that compounding comorbidities, such as coronary artery disease (CAD), hypertension and body mass index
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(BMI), alone do not influence the observed mitochondrial dysfunction in the type 2
diabetic SSM.
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MATERIALS AND METHODS

Human Patient Population
The West Virginia University Institutional Review Board and Institutional
Biosafety Committee approved all protocols. Individuals undergoing coronary artery
bypass graft surgery or cardiac valve replacement at Ruby Memorial Hospital
consented for the release of their cardiac tissue to West Virginia University School of
Medicine. Consenting individuals were then characterized as non-diabetic or diabetic
based upon prior diagnosis of diabetes mellitus. All demographic and clinical data are
shown in Table 1.

Individual Mitochondrial Subpopulations Isolation
Right atrial appendages were removed from patients and rinsed in phosphate
buffered saline (PBS, pH 7.4). Pericardial fat was then trimmed and the heart tissue was
weighed. The SSM and IFM were isolated as previously described by Palmer et al. (23)
with modifications by our laboratory (15, 16, 33). Mitochondrial pellets were
resuspended in KME buffer (100 mM KCl, 50 mM MOPS, and 0.5 mM EDTA) for
mitochondrial

respiration,

flow

cytometric

analyses,

and

enzymatic

activity

measurements. Protein content was determined by the Bradford method using bovine
serum albumin as a standard (9).
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Mitochondrial Size, Internal Complexity and Membrane Potential
Mitochondrial

subpopulation

size,

internal

complexity

and

mitochondrial

membrane potential were examined as previously described by our laboratory with
modifications (13, 15, 33). Briefly, flow cytometric analyses were performed using a
FACS Calibur equipped with a 15-MW 488-nm argon laser and 633-nm red diode laser
(Becton Dickinson, San Jose, CA). The ratiometric dye 5,5’,6,6’-tetrachloro-1,1’,3,3’tetraethylbenzimidazol carbocyanine iodide (JC-1; Molecular Probes, Carlsbad, CA),
was used to selectively stain and gate for respiring mitochondria. Freshly isolated
mitochondrial subpopulations were incubated with JC-1 for 15 min at 37°C, and the
samples were run for 30 seconds. Forward scatter (FSC) and side scatter (SSC)
detectors were used to examine size (FSC) and complexity (SSC) in isolated
mitochondrial subpopulations. Changes in membrane potential were recorded as the
ratio between the color change from green to orange. Measurements were performed
on freshly isolated mitochondrial subpopulations. All flow cytometric measurements
were performed in conjunction with the West Virginia University Flow Cytometry Core
Facility.

Mitochondrial Respiration Rates
State 3 and state 4 respiration rates were measured in isolated mitochondrial
subpopulations as previously described (11, 12, 18), with modifications (16). Briefly,
isolated mitochondrial subpopulations were resuspended in KME buffer. Protein content
was determined by the Bradford method (9). Fifty micrograms of protein was added to
respiration buffer (80 mmol/l KCl, 50 mmol/l MOPS, 1 mmol/l EGTA, 5 mmol/l KH2PO4,
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and 1 mg/ml BSA) and placed into the respiration chamber connected to an oxygen
probe (OX1LP-1mL Dissolved Oxygen Package, Qubit System, Kingston, ON, Canada).
Maximal glucose-mediated respiration was initiated by the addition of glutamate (5 mM)
and malate (5 mM). Maximal fatty acid-mediated respiration was initiated by the addition
of palmitoylcarnitine (40 µM) and malate (5 mM). Measurements of state 3 (250 mM
ADP) and state 4 (ADP-limited) respiration were made as previously described (7).
Values were expressed as nmol of oxygen consumed -min-1-mg protein-1.

Electron Transport Chain (ETC) Complex Activities
Complex

I,

complex

III,

and

complex

IV

activities

were

measured

spectrophotometrically as previously described (13, 15, 16, 29). Complex I activity was
determined by measuring the oxidation of NADH at 340 nm and complex III activity was
determined by measuring the reduction of cytochrome c at 550 nm in the presence of
reduced decylubiquinone (50 µM). Complex IV activity was determined by measuring
the oxidation of cytochrome c at 550 nm. Protein content

was determined by the

Bradford method (9), and values were expressed as activities (in nmol substrate
consumed·min-1·mg protein-1).

Electron Transport Chain Complex Protein Expression
To assess electron transport chain complex I and IV abundance within the nondiabetic and diabetic human heart, blue native polyacrylamide gel electrophoresis (BNPAGE) was performed according to the manufacturer's protocol (Invitrogen, Carlsbad,
CA). Briefly, 20 μg of isolated mitochondria were solubilized with 1% digitonin for 15 min
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on ice. After addition of 1.25 μl of Coomassie G-250, samples were run on 4–16%
NativePAGE gels at 120 V for 90 min at room temperature. Gels were transferred to
PDVF membranes and subsequently probed with an anti-ND-1 goat antibody (Product
No. 20493, Santa Cruz, CA) and an anti-cytochrome c oxidase rabbit antibody (product
No. ab16056, Abcam, Cambridge, MA). The secondary antibodies used were a donkey
anti-goat IgG horseradish peroxidase conjugate (Product No. 2020, Santa Cruz, CA)
and a goat anti-rabbit IgG horseradish peroxidase conjugate (product No. 10004301,
Cayman Chemical Company, Ann Arbor, MI).
according

to

the

Pierce

ECL Western

Detection of signal was performed

Blotting

Substrate

detection

system

manufacturer’s directions (Thermo Fisher Scientific, Rockford, IL). Quantification of
chemiluminescent signals were assessed using a G:Box Bioimaging System (Syngene,
Frederick, MD), and the data captured using GeneSnap software (Syngene, Frederick,
MD). Densitometry was measured using Image J Software (National Institutes of Health,
Bethesda, MD).

Statistics
Means and SEM were calculated for all data sets. Data shown in Table 1 and in
all subsequent figures were analyzed with a Student’s t-test. P < 0.05 was considered
statistically significant. Logistic regression was performed to determine if any comorbities were associated with being diabetic. For patients with HbA1c measurements,
the relationship between HbA1c and the outcomes were assessed using a linear spline
model with a break-point at HbA1c equal to 6.5%. The World Health Organization states
that a patient is considered diabetic if HbA1c level is equal to or greater than 6.5% (32).
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This allowed for different linear relationships for those with HbA1c less than 6.5% and
those above 6.5%. The relationship between blood glucose levels and the outcomes
were also assessed using a linear spline model with a break-point at a blood glucose
level equal to 200 mg/dL, which is the level used by the American Diabetes Association
to diagnose a patient as diabetic (1).
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RESULTS

Patient Characteristics Table
As seen in Table 3.1, eighty one patients were separated into two groups, nondiabetics and diabetics, based on prior diagnosis. The ages and sexes between the two
groups were similarly distributed and all the patients were Caucasian. The diabetic
patients had significantly higher BMI levels, higher HbA1c levels, as well as higher
blood glucose levels (P < 0.05 for all three). Greater than 80% of both populations had
hypertension and CAD. Medications that the patients were receiving were also noted.
Diabetic patients were actively receiving medications, such as Metformin or insulin, as
treatment for diabetes mellitus. The majority of patients regardless of diabetic status
were receiving beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors and/or 3hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins).

Mitochondrial Morphology and Membrane Potential
Literature

has

suggested

that

mitochondrial

dysfunction

contributes

to

mitochondrial morphological alterations (13, 19, 25). Isolated mitochondria were
analyzed by flow cytometry using a dye that only migrates into respiring mitochondria
that contain a membrane potential. The mitochondria that were respiring were gated,
which allowed only those mitochondria, and not debris, to be measured. Forward and
side scatter histograms revealed two different populations, as determined by size and
complexity (Figure 3.1A and 3.1B, respectively). No differences in mitochondrial size or
internal complexity were observed between diabetic and non-diabetic patients for either
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subpopulation (Figures 3.1C and 3.1D). Although we did not see an alteration in
mitochondrial size and internal complexity due to type 2 diabetes mellitus, we observed
that the SSM were larger in size and had a greater internal complexity compared to IFM
(P < 0.05; Figure 3.1C and 3.1D, respectively), which is supported by previous findings
in mouse models (13, 15, 33).

Using a mouse model, our laboratory has previously reported higher membrane
potential in the IFM compared to the SSM measured by flow cytometry (5, 15). In the
human heart, IFM exhibited a greater membrane potential compared to SSM but no
change was observed between non-diabetic and diabetic patients (P < 0.05; Figure
3.1E).

Mitochondrial Respiration
Mitochondrial respiration rates were measured in isolated mitochondrial
subpopulations from non-diabetic and diabetic patients. When using glutamate and
malate as substrates to measure maximal glucose-mediated respiration, diabetic SSM
displayed significantly decreased state 3 and state 4 respiration rates as compared to
the non-diabetic SSM (P < 0.05; Figure 3.2A), with no differences observed in the IFM
(Figure 3.2B).

Glycolysis is impaired during type 2 diabetes mellitus; therefore, the heart must
rely primarily on fatty acid oxidation as an energy source (2). When using
palmitoylcarnitine and malate as substrates to measure maximal fatty-acid respiration,
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both state 3 and state 4 respiration rates in the diabetic SSM were significantly
decreased (P < 0.05; Figure 3.2C), with no change for either state in the IFM (Figure
3.2D).

To determine whether the degree of hyperglycemia and HbA1c level was
predictive of the mitochondrial dysfunction we observed in diabetic patients, we
generated spline models to determine correlative risk. In Figures 3.3A and 3.3B, state 3
respiration rates were plotted against HbA1c levels, whereas in Figures 3.3C and 3.3D,
state 3 respiration rates were plotted against blood glucose levels. In each model, we
selected a break-point (dashed line) that represented the value at which a diagnosis of
diabetes mellitus is performed in a clinical setting. For HbA1c a value of 6.5% was
selected while for blood glucose, a value of 200 mg/dL was selected. Both of these
values are used to make a diabetic diagnosis (1, 32). In Figures 3.3A and 3.3C, nondiabetic patients (left of the dashed line) displayed linear correlations suggestive of
decreased state 3 respiration rates with increasing HbA1c or blood glucose level. In
contrast, diabetic patients (right of the dashed line), displayed linear correlations
indicating lower state 3 respiration rates which were similar regardless of increasing
HbA1c or blood glucose level (Figures 3.3A and 3.3C). Contrary to SSM, The similar
analyses in IFM indicated linear slopes that were more similar between diabetic and
non-diabetic patients (Figures 3.3B and 3.3D).
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Electron Transport Chain Complex Activities
Mitochondrial function was further examined by measuring ETC complex
activities. As seen in Figure 3.4, ETC complexes I and IV activities were significantly
decreased in the SSM of type 2 diabetic patients relative to non-diabetics (P < 0.05,
Figure 3.4A). ETC complex III did not differ in the SSM of non-diabetic and diabetic
patients. ETC complexes I, III and IV activities were not altered in diabetic IFM as
compared to non-diabetic IFM (Figure 3.4B).

As above, we determined whether the degree of hyperglycemia and HbA1c level
was predictive of the ETC complex I functional decrement observed in diabetic patients,
using a spline model. In Figures 3.5A and 3.5B, ETC complex I activities were plotted
against HbA1c levels, whereas in Figures 3.5C and 3.5D, ETC complex I activities were
plotted against blood glucose levels. In Figures 3.5A and 3.5C, non-diabetic patients
(left of the dashed line) displayed linear correlations suggestive of decreased ETC
complex I activity with increasing HbA1c or blood glucose level. In contrast, diabetic
patients (right of the dashed line), displayed linear correlations indicating lower ETC
complex I activity which was similar regardless of increasing HbA1c or blood glucose
level (Figures 3.5A and 3.5C). As above, similar analyses in IFM indicated linear slopes
that were more similar between diabetic and non-diabetic patients (Figures 3.5B and
3.5D).
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Examination of Electron Transport Chain Complex Protein Expression
To determine whether loss of ETC complexes was associated with decreased
enzymatic activity, we assessed the protein content of ETC complexes by BN-PAGE.
Both ETC complex I and complex IV were significantly decreased in the diabetic SSM
(P < 0.05, Figures 3.6A and 3.7A, respectively). In contrast, no differences in protein
content for ETC complexes I or complex IV in the diabetic IFM compared to nondiabetic IFM (Figures 3.6B and 3.7B, respectively). These results suggest a possible
mechanism underlying the observed decrease in mitochondrial function of the diabetic
SSM compared to the non-diabetic SSM.

Presence of Type 2 Diabetes Mellitus, Coronary Artery Disease and Hypertension
Because many of the patients studied possessed other comorbidities, we were
not able to separate the diabetic patients from the non-diabetic patients without
including those with both CAD and hypertension. Nevertheless, we attempted to
determine whether the presence of a specific comorbidity was responsible for the
observed effects on mitochondrial function. Patients were grouped into three categories:
(1) non-diabetic and diabetic patients with both CAD and hypertension; (2) non-CAD
and CAD patients without diabetes mellitus; and (3) non-hypertensive and hypertensive
patients without diabetes mellitus. These groups were chosen because they enabled us
to isolate out the individual comorbidities without the presence of diabetes mellitus
(groups 2 and 3) and enable comparison with diabetic and non-diabetic patients who
possessed both comorbidities (group 1). Table 3.2 displays the mitochondrial functional
analyses of non-diabetic and diabetic patients who all have CAD and hypertension and
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the data shows a decrease in both mitochondrial respiration and ETC complex I and IV
activity of diabetic patients who have CAD and hypertension. Table 3.3 represents
mitochondrial functional analyses of patients who had or did not have CAD, of which
none of the patients were hypertensive or diabetic and results indicated no observed
mitochondrial dysfunction in the patients who possessed CAD. Table 3.4 illustrates the
mitochondrial functional analyses of patients who were or were not hypertensive, of
which none had CAD or were diabetic and similarly, data demonstrated that the
mitochondrial function of these hypertensive patients. These results suggest that the
mitochondrial dysfunction observed in type 2 diabetic patients who have both CAD and
hypertension is not due to either CAD or hypertension independently.

The Influence of Body Mass Index (BMI) on Type 2 Diabetes Mellitus
We sought to determine the influence of BMI on SSM mitochondrial function
during type 2 diabetes mellitus using a similar spline approach. The linear spline models
in Figures 3.8A and 3.8B include a break-point at an HbA1c level equal to 6.5% (dashed
line). Based on the World Health Organization, patients whose BMI is less than 30
kg/m2 are considered non-obese, whereas patients whose BMI is greater than 30 kg/m 2
are considered obese (31). Patients with a BMI < 30 kg/m2 are indicated in white while
those patients with a BMI > 30 kg/m2 are indicated in black (Figures 3.8A and 3.8B).
After categorizing the patients as non-obese or obese, we were able to visualize the
impact of obesity on these two measurements of mitochondrial function (Figure 3.8). If
obesity were impacting mitochondrial function to a great extent, we would expect to see
the obese patients clustered at the bottom of the spline model, indicating a lower
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mitochondrial function compared to the non-obese patients. Interestingly, we observed
an even displacement of the obese patients throughout the patients’ data, indicating that
obesity does not independently impact mitochondrial function, specifically SSM state 3
respiration and SSM ETC complex I activity as measured by HbA1c levels. Our results
indicated that SSM state 3 respiration (Figure 3.8A) and SSM ETC complex I activity
(Figure 3.8B) are not correlated with a patient’s BMI, regardless of diabetic status.
These findings suggest that the BMI level of an individual is not an effective predictor of
type 2 diabetic status nor mitochondrial dysfunction.
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DISCUSSION

Mitochondrial dysfunction contributes to cardiovascular complications that are
associated with type 2 diabetes mellitus (13, 19, 24, 25). The existence of two
mitochondrial subpopulations present in the cardiomyocyte further complicates
mitochondrial functional analyses. Our laboratory and others have reported that these
two separate pools of mitochondria are affected differently by pathologies, such as
diabetes mellitus in rodent models (13, 14, 21, 22). Limited research has used a human
heart model to examine mitochondrial function (30) and the effects of diabetes mellitus
(3, 4). The goal of this translational study was to determine how type 2 diabetes mellitus
affects individual mitochondrial subpopulations in human patients. Our results suggest
that mitochondrial dysfunction is present in the heart of human type 2 diabetic patients,
with the SSM being affected to a greater extent than the IFM, as demonstrated by
decreased glucose- and fatty acid–mediated respiration, ETC complex I and IV activities
and complex expression.

With our large data set, we were able to analyze relationships between nondiabetics and diabetics by examining state 3 mitochondrial respiration and ETC complex
I activities. By utilizing linear regression spline models for state 3 mitochondrial
respiration as well as ETC complex I activity and separating non-diabetic and diabetic
patients by HbA1c levels, a decreasing slope for non-diabetic patients suggested that
as HbA1c level increases, SSM state 3 respiration and ETC complex I activity
decreases. Once an HbA1c level of 6.5% is reached, the slope of the linear regression
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remains somewhat flat despite further increases in HbA1c levels. These findings
indicate that mitochondrial dysfunction is already present in diabetics with HbA1c levels
in the modestly elevated range and that as HbA1c levels increase the extent of
mitochondrial dysfunction remains the same. A similar phenomenon is apparent when
analyzing SSM state 3 respiration and SSM ETC complex I activity and applying a
spline model which utilizes a blood glucose level of 200 mg/dL. Taken together these
findings indicate that mitochondrial dysfunction in the SSM of type 2 diabetic patients is
present despite the degree of control over key indices that are predictive of patient
morbidity, such as HbA1c and blood glucose levels. Further, these findings may
suggest that the presence of the diabetic phenotype independent of the stage or timing
of the disease is associated with dysfunctional profiles to cardiac mitochondria.

When analyzing the spline models of state 3 respiration and ETC complex
activity I measured by blood glucose levels, similar relationships are observed as
compared to examining these mitochondrial functional parameters measured by HbA1c
levels. In regards to SSM state 3 respiration, the linear regression slope before a blood
glucose level of 200 mg/dL is noticeably decreasing, with no visible slope for the
diabetic patients whose blood glucose levels are higher than 200 mg/dL. By comparing
the two relationships of SSM state 3 mitochondrial respiration between non-diabetic and
diabetic patients, we were able to determine that SSM state 3 respiration decreased
with increasing blood glucose levels until a blood glucose level of 200 mg/dL is reached,
from which no correlation between mitochondrial dysfunction and increasing blood
glucose levels existed. The spline model of SSM ETC complex activity I measured by
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blood glucose levels also revealed a similar phenomenon; however, the linear
regression slope was not as dramatic as with SSM state 3 respiration. With that being
said, SSM ETC complex I activity decreased with increasing blood glucose levels until a
blood glucose level of 200 mg/dL was reached. Past this threshold, SSM ETC complex I
activity dysfunction remained constant, regardless of increasing blood glucose levels.

In contrast to our current study, Rosca et al. reported increased ETC complex I
and complex III expression levels in the SSM, with no change in ETC complex IV in a
canine coronary heart failure model as measured by BN-PAGE (27). It is unclear why
the results from our study differed by may be due in part to differences in the
pathologies, heart failure vs. diabetes mellitus, as well as the examination of canine and
human models. Anderson et al (4) reported no change in ETC complexes I-V
expression in diabetic patients when compared to non-diabetics. This difference may be
due to the experimental procedures employed. Anderson et al. examined polypeptides
from denatured proteins as opposed to the protein expression of the individual complex
as a whole unit, which was the case in our study. This difference could also be
explained by the examination of homogenate versus mitochondrial subpopulations used
in the current study.

Examining mitochondrial function in the human heart does not come without
critical limitations. First, the biopsies are collecting come from individuals undergoing
cardiac procedures, which may impart negative effects on the heart. Despite this
complication, we feel that the non-diabetic group of patients is the appropriate group to
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compare with the diabetic patients because the clinical variables and medications that
may influence the results are no longer taken into consideration due to the fact that the
both groups have similar clinical variables, such as CAD, hypertension, and medications
(Table 3.1).

The presence of other clinical co-morbidities has been a factor in the examination
of the human heart because most of the patients who are undergoing cardiac
procedures are diagnosed with a multitude of compounding diseases, such as CAD,
type 2 diabetes mellitus and hypertension. Although the patients that were diagnosed
with these illnesses were similarly distributed in both groups (Table 3.1), it is unclear as
to which disease was affecting the mitochondrial functional outcomes. In this study, we
were able to determine that CAD, hypertension nor BMI alone were the prominent
contributing factor to the observed mitochondrial dysfunction (Tables 3.3 and 3.4, and
Figure 3.8, respectively) in patients with type 2 diabetes mellitus. Our data is in
agreement with Anderson et al. (4) and indicates that type 2 diabetes mellitus, in the
presence of CAD and hypertension, is part of a multifaceted interaction that all together
contributes to mitochondrial dysfunction (Table 3.2). Although we had a large patient
number, we were unable to separate the effects of type 2 diabetes mellitus alone on
mitochondrial functionality.

In conclusion, we are the first to demonstrate mitochondrial subpopulationspecific dysfunction in the human heart of type 2 diabetic patients, with the SSM being
impacted to a greater extent than the IFM. With the use of linear spline models, we were
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able to illustrate that once a threshold is reached, either with HbA1c or blood glucose
levels, mitochondrial dysfunction is no longer correlated with decreasing levels,
highlighting the importance of preserving mitochondrial function regardless of the stage
of type 2 diabetic onset.
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Figure 3.1 Mitochondrial characteristics. Cardiac mitochondrial subpopulations were
isolated and incubated with JC-1 dye. Forward scatter and side scatter were used to
analyze the isolated mitochondria as seen by a (A) representative histogram of nondiabetic SSM; and a (B) representative histogram of non-diabetic IFM. Mitochondrial
size (C) and internal complexity (D) was quantified for each mitochondrial
subpopulation. By calculating the ratio of green to orange fluorescence, membrane
potential (E) was quantified for non-diabetic and diabetic SSM and IFM. Closed bars
represent non-diabetic patients and open bars represent diabetic patients. *P < 0.05
SSM non-diabetic vs. IFM non-diabetic; N = 28 non-diabetics and 23 diabetics.
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Figure 3.2
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Figure 3.2 Mitochondrial subpopulation respiration rates. Cardiac mitochondrial
subpopulations were isolated and respiration rates were measured using different
substrates. Glutamate and malate were used as substrates to measure the amount of
oxygen consumed (State 3 and State 4) for (A) non-diabetic and diabetic SSM and (B)
non-diabetic

and

diabetic

IFM

(N

=

28

non-diabetics

and

23

diabetics).

Palmitoylcarnitine and malate were used as substrates to measure the amount of
oxygen consumed (State 3 and State 4) for (C) non-diabetic and diabetic SSM and (D)
non-diabetic and diabetic IFM (N = 17 non-diabetics and 10 diabetics). Values are mean
+ SEM. Units are nmoles O2 consumed/min/mg of protein. Closed bars represent nondiabetic patients and open bars represent diabetic patients. *P < 0.05 State 3 SSM nondiabetic vs. State 3 SSM diabetic. †P < 0.05 State 4 SSM non-diabetic vs. State 4 SSM
diabetic.
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Figure 3.3 Linear spline illustrations for mitochondrial respiration. Linear spline
models for HbA1c and mitochondrial respiration, specifically state 3, were performed
with a break-point at an HbA1c level equal to 6.5% (dashed line). The linear relationship
before and after the break-point are plotted for SSM (A) and IFM (B) with dots
representing each patient with an observed HbA1c level. A linear spline model for blood
glucose and state 3 mitochondrial respiration was performed with a break-point at a
blood glucose level equal to 200 mg/dL (dashed line). The linear relationship before and
after the break-point are plotted for SSM (C) and IFM (D) with dots representing each
patient with an observed blood glucose level. Units are nmoles O 2 consumed/min/mg of
protein.
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Figure 3.4 Electron transport chain activities in mitochondrial subpopulations.
Cardiac mitochondrial subpopulations were isolated and ETC complex I, III, and IV
activities were measured. ETC complexes I, III, and IV in the non-diabetic and diabetic
SSM (A) and IFM (B). Values are mean + SEM. Units are activity/min/mg of protein.
Closed bars represent non-diabetic patients and open bars represent diabetic patients.
*P < 0.05 SSM non-diabetic vs. SSM diabetic; N = 47 non-diabetics and 34 diabetics.

134

Figure 3.5
SSM ETC Complex I Activity measured by HbA1c levels
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SSM ETC Complex I Activity measured by blood glucose levels

SSM ETC Complex I Activity
activity/min/mg protein

C.

Blood glucose

IFM ETC Complex I Activity measured by blood glucose levels

IFM ETC Complex I Activity
activity/min/mg protein

D.

Blood glucose
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Figure 3.5 Linear spline illustrations for electron transport chain complex I
activity. Linear spline models for HbA1c and ETC complex I activity, were performed
with a break-point at an HbA1c level equal to 6.5% (dashed line). The linear relationship
before and after the break-point are plotted for SSM (A) and IFM (B) with dots
representing each patient with an observed HbA1c level. A linear spline model for blood
glucose and ETC complex I activity was performed with a break-point at blood glucose
level equal to 200 mg/dL (dashed line). The linear relationship before and after the
break-point are plotted for SSM (C) IFM (D) with dots representing each patient with an
observed blood glucose level. Units are activity/min/mg of protein.
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Figure 3.6
A.
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Complex I
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IFM: Complex I

Figure 3.6 Electron transport chain complex I expression. Cardiac mitochondrial
subpopulations were isolated and subjected to BN-PAGE to measure complex I protein
content. A component of ETC complex I was used to measure the protein content of
complex I. The BN-PAGE blots are illustrated in the non-diabetic and diabetic SSM (A)
and IFM (C). The optical density was calculated in non-diabetic and diabetic SSM (B)
and IFM (D). Values are mean + SEM. Closed bars represent non-diabetic patients and
open bars represent diabetic patients. *P < 0.05 SSM non-diabetic vs. SSM diabetic; N
= 4 non-diabetics and 4 diabetics.
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Figure 3.7
A.
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IFM: Complex IV

Figure 3.7 Electron transport chain complex IV expression. Cardiac mitochondrial
subpopulations were isolated and subjected to BN-PAGE to measure complex I and
complex IV protein content. A component of ETC complex IV was used to measure the
protein content of complex IV. The BN-PAGE blots are illustrated in the non-diabetic
and diabetic SSM (A) and IFM (C). The optical density was calculated in non-diabetic
and diabetic SSM (B) and IFM (D). Values are mean + SEM. Closed bars represent
non-diabetic patients and open bars represent diabetic patients. *P < 0.05 SSM nondiabetic vs. SSM diabetic; N = 4 non-diabetics and 4 diabetics.
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Figure 3.8 Linear spline illustration for state 3 mitochondrial respiration and ETC
complex I activity. Linear spline models for HbA1c and SSM state 3 mitochondrial
respiration and SSM ETC complex I activity, respectively, with a break-point at an
HbA1c levelg equal to 6.5% (dashed line). (A) Same linear spline model as Figure 3.3A
and (B) is the same graph as Figure 3.5A, with dots representing each patient with an
observed HbA1c level. Open dots represent patients whose BMI is less than 30 kg/m 2,
whereas closed dots represent patients whose BMI is greater than 30 kg/m 2. Units are
nmoles O2 consumed/min/mg of protein for mitochondrial respiration and activity/min/mg
of protein for ETC complex I activity.
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Table 3.1

Demographics

Non-diabetic

Diabetic

60.0 + 1.9

61.2 + 1.8

38/9

22/12

Race

Caucasian

Caucasian

BMI

29.8 + 0.8

32.8 + 1.1*

5.5 + 0.1

8.5 + 0.4*

Avg. BG (n=37,33)

111.8 + 2.4

199.2 + 12.2*

EF

52.8 + 2.1

49.2 + 2.7

Hypertension (n=46,34)

78.3%

85.3%

CAD (n=47,34)

83.0%

91.2%

Insulin

0/47

12/34

Metformin

0/47

13/34

Sulfonylureas

0/47

6/34

β-blockers

28/47

26/34

ACE inhibitors

15/47

17/34

Statins

27/47

20/34

Age (years)
Sex (M/F)

Characteristics

HbA1c

Medications

(n=37,33)
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Table 3.1 Patient Demographics and Characteristics. * P < 0.05 Diabetic vs. Nondiabetic group.
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Table 3.2
SSM

State 3

State 4

Complex I

Complex III

Complex IV

Nondiabetic

65.8 ± 8.4

4.1 ± 0.9

42.9 ± 3.6

24.6 ± 4.9

16.8 ± 2.1

Diabetic

39.4 ± 6.0*

1.8 ± 0.3*

30.1 ± 2.7*

24.58 ± 4.6

11.0 ± 1.3*

Nondiabetic

35.6 ± 5.5

3.4 ± 1.0

54.6 ± 8.5

51.8 ± 11.5

33.3 ± 6.5

Diabetic

37.4 ± 3.9

2.3 ± 0.6

48.9 ± 5.2

50.6 ± 10.7

24.1 ± 4.8

IFM
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Table 3.2 Non-diabetic and Diabetic Patients with Both Coronary Artery Diseases
and Hypertension. All patients have both coronary artery disease and hypertension.
Diabetes mellitus is the only variable in this data set. Values are mean + SEM. Units for
State 3 and State 4 are nmoles of oxygen consumed/min/mg of protein (N = 21 Nondiabetics and 20 Diabetic patients). Units from complex activities are activity/min/mg of
protein (N = 34 Non-diabetics and 27 Diabetic patients).*P<0.05 Diabetic vs. nondiabetic group.
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Table 3.3
SSM

State 3

State 4

Complex I

Complex III

Complex IV

NonCAD

82.5 ± 10.7

4.0 ± 0.8

41.8 ± 3.3

23.0 ± 4.4

16.3 ± 1.9

CAD

84.8 ± 27.6

4.5 ± 0.9

47.2 ± 10.1

21.8 ± 7.8

20.7 ± 3.3

NonCAD

41.8 ± 6.0

3.3 ± 0.8

53.6 ± 7.5

50.3 ± 10.1

32.2 ± 5.7

CAD

24.7 ± 6.5

3.6 ± 0.9

53.9 ± 10.8

18.4 ± 3.1

37.0 ± 9.5

IFM
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Table 3.3 Non-Coronary Artery Diseases (CAD) and CAD Patients without
Diabetes Mellitus. None of the patients have diabetes mellitus or hypertension.
Coronary artery disease is the only variable in this data set. Values are mean + SEM.
Units for State 3 and State 4 are nmoles of oxygen consumed/min/mg of protein (N = 28
Non-CAD and 4 CAD patients). Units from complex activities are activity/min/mg of
protein (N = 42 Non-CAD and 8 CAD patients).
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Table 3.4
SSM

State 3

State 4

Complex I

Complex III

Complex IV

Non-HT

74 ± 10.8

4.1 ± 0.9

42.8 ± 3.6

24.5 ± 4.7

17.4 ± 2.1

110.5 ± 20.4

3.8 ± 0.8

42.5 ± 7.2

17.1 ± 5.4

16.0 ± 2.7

Non-HT

34.7 ± 5.4

3.3 ± 0.9

54.7 ± 8.2

50.6 ± 11.2

34.2 ± 6.4

HT

54.6 ± 13.6

3.3 ± 0.7

50.1 ± 7.3

29.1 ± 7.3

29.0 ± 6.4

HT
IFM
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Table 3.4 Non-Hypertensive (HT) and Hypertensive Patients without Diabetes
Mellitus. None of the patients have diabetes mellitus or coronary artery disease.
Hypertension is the only variable in this data set. Values are mean + SEM. Units for
State 3 and State 4 are nmoles of oxygen consumed/min/mg of protein (N = 25 Nonhypertensive (Non-HT) and 7 Hypertensive (HT)). Units from complex activities are
activity/min/mg of protein (N = 40 Non-hypertensive and 10 Hypertensive patients).

151

Chapter 4:
General Discussion

GENERAL DISCUSSION

The overall objective of this dissertation was to evaluate the impact of both type
1 and type 2 diabetes mellitus on the IMM. Specifically, we wanted (1) to determine how
the cardiolipin biosynthesis pathway and cardiolipin-protein interactions were impacted
by type 1 diabetes mellitus; (2) to determine the therapeutic value of mitochondrial
Grp75 overexpression on mitochondrial protein import during a type 1 diabetic insult;
and (3) to examine how mitochondrial subpopulations in the human heart were affected
by type 2 diabetes mellitus. The long term goal was to understand the importance of
IMM preservation during diabetes mellitus and to translate rodent mitochondrial
dysfunction that occurs during diabetic cardiomyopathy to the human diabetic heart.
The central hypothesis of this dissertation was that the mitochondrion is negatively
impacted by diabetes mellitus, leading to deleterious effects to the IMM and
compromising the proteins associated with cardiolipin and protein import, which will
translate to the diabetic human heart. The rationale for the research conducted for this
dissertation is based on the importance of preserving the IMM structure and processes
within to alleviate mitochondrial dysfunction associated with the diabetic heart, as well
as understanding the effect of diabetes mellitus on human cardiac mitochondrial
subpopulations.

Cardiovascular complications, such as diabetic cardiomyopathy, are the leading
cause of morbidity and mortality in patients with diabetes mellitus (13, 15, 25). Multiple
studies have linked mitochondrial dysfunction with diabetic cardiomyopathy (3, 9, 10,
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23, 30, 31). Mitochondrial studies are complex in the fact that two distinct mitochondrial
subpopulations reside in the heart (Figure 1.1). These two spatially distinct pools of
mitochondria respond differently to pathological insults, such as diabetes mellitus (7-9,
18, 20, 24). We have previously reported mitochondrial dysfunction in the type 1
diabetic mouse heart, specifically in IFM, as evidenced by decreased mitochondrial
respiration, ETC complexes I, III, IV, and V activities, as well as protein import (3, 9).
Along with increased ROS production, lipid peroxidation and nitrotyrosine residues were
significantly increased (9). Our laboratory has also reported detriments to the IMM and
subsequent mitochondrial dysfunction, specifically in SSM of a type 2 db/db mouse
model (8, 24), as evidenced by decreased mitochondrial respiration and decreased
Grp75 protein content. We were the first to evaluate the impact of type 2 diabetes
mellitus on mitochondrial subpopulations in human atrial tissue from which the results
previously reported from the db/db mouse heart translated into the type 2 diabetic
human model, suggesting that mitochondria function from type 2 diabetic human heart
displays similar mitochondrial dysfunctional profiles with SSM primarily impacted.

Literature suggests that ROS production is the underlying mechanism
contributing to the mitochondrial dysfunction associated with diabetes mellitus (6, 14).
The main source of ROS production is the IMM, making this membrane more
susceptible to oxidative damage. The IMM is composed of a specific lipid environment
that houses many of the critical mitochondrial processes that are required for
mitochondria to function properly (Figure 1.2), such as oxidative phosphorylation and
protein import machinery. Our laboratory has reported proteomic alterations in the IFM
during a type 1 diabetic insult and in the SSM during a type 2 diabetic insult (3, 8).
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Figure 4.1A represents the mitochondrial proteome and the abundance of proteins
present in each membrane of the mitochondrion. Of the proteins altered during a type 1
diabetic insult, 51% reside in the IMM (Figure 4.1B). Similarly, of the proteins altered
during a type 2 diabetic insult, 50% reside in the IMM (Figure 4.1C). By comparing the
pie charts between the different disease states versus control, one can recognize that
the IMM is most affected by diabetes mellitus (17).

A.

Mitochondrial Proteome
Mitochondrial compartments:
 OMM = outer mitochondrial membrane
 IMM = inner mitochondrial membrane
 IMS = inner mitochondrial space

 Matrix

B.

Type 1 Diabetic IFM

C.

Type 2 Diabetic SSM

Figure 4.1. Mitochondrial proteome during different diabetic states. (A) Pie chart
representing the percentage of proteins present in each membrane of mitochondria in a
control setting. (B) Pie chart representing the percentage of proteins altered during a
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type 1 diabetic insult in the IFM. (C) Pie chart representing the percentage of proteins
altered during a type 2 diabetic insult in the SSM (17).

Cardiolipin is a key phospholipid that is required for the stability of the IMM (27),
as well as for proper functioning of many IMM proteins (Figure 1.3), including the
oxidative phosphorylation machinery, cytochrome c attachment and protein import
machinery (12, 19, 22, 28, 32). Tetralinoleic cardiolipin is the most dominant form of
cardiolipin in the heart; however, other forms exist in different tissues and during
different pathologies (1, 27). Our laboratory and others reported a decrease in total
cardiolipin and tetralinoleic cardiolipin during a type 1 diabetic insult (Chapter 2) (16),
specifically in IFM (9). Preliminary data generated from type 2 diabetic human atrial
tissue utilizing high performance thin layer chromatography also revealed lower total
cardiolipin content in the diabetic SSM (not significant) (Figure 6.5).

Although both type 1 and type 2 diabetes mellitus are a consequence of a
hyperglycemic environment, the manifestation and phenotypes between the diseases
differ. For example, chapters 2 and 6 reported decreased cardiolipin content in both IFM
(type 1) and SSM (type 2), which could be caused by different pathways depending on
the type of diabetes mellitus. During type 2 diabetes mellitus, fatty acid oxidation and
oxidative stress precede the hyperglycemic environment (5), from which circulating fatty
acids, as well as triglyceride levels, are increased (33). Because SSM are located just
beneath the sarcolemma, this population is affected to a greater extent than IFM during
type 2 diabetes mellitus. Supporting this statement, proteins involved in fatty acid
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oxidation were reported to be increased to a greater extent in type 2 diabetic SSM,
compared to IFM, resulting in an enhanced lipid environment (8). Literature has also
stated that individuals with type 2 diabetes mellitus tend to be more obese and were
subjected to myocardial lipotoxicity (4); therefore, cardiolipin content could be
decreased in type 2 diabetic SSM due to the enhanced oxidative environment and
increased lipotoxicity.

During type 1 diabetes mellitus, the hyperglycemic environment causes an
enhanced oxidative environment, from which post-translational modification analyses
revealed a higher number of oxidations in type 1 diabetic IFM, compared to type 2
diabetic SSM. This enhanced oxidative environment is a result of increased ROS
production that damages important proteins and subsequent processes that are
required for proper mitochondrial function. Along with a higher membrane potential, IFM
have higher respiration and protein import rates compared to SSM. Because of these
characteristics, type 1 diabetic IFM produce higher levels of ROS; and consequently,
are impacted to a greater extent than SSM. Although the reported decrease in
cardiolipin content in type 1 diabetic IFM could also be caused by the oxidative
environment, data reported in chapter 2 indicated that an important constituent required
for cardiolipin biosynthesis was significantly decreased; therefore, the enhanced
oxidative environment could be the underlying mechanism contributing to the defective
biosynthesis of cardiolipin. To identify the mechanism contributing to decreased
cardiolipin content, we first evaluated the biosynthetic pathway of cardiolipin during a
type 1 diabetic insult (Chapter 2).
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The cardiolipin biosynthetic pathway is a multi-step process that requires many
enzymatic reactions to occur in order for the mature form of cardiolipin to be produced
(Figures 1.4 and 2.1) (26, 27). We hypothesized that at least one of the reactions
involved in this pathway was affected by type 1 diabetes mellitus. The mRNA and
protein levels of the enzymes directly responsible for the synthesis of cardiolipin were
analyzed and results indicated that none of the mRNA levels were altered in the diabetic
heart; and interestingly, only one protein was significantly decreased in the type 1
diabetic IFM – CRLS (Table 2.1 and Figure 2.2). Because the protein content of CRLS
was decreased, we next analyzed its activity and found that CRLS activity was
significantly decreased in the type 1 diabetic IFM (Figure 2.3). These results taken
together suggest that the main contributors to the loss of cardiolipin content during both
type 1 and type 2 diabetes mellitus is decreased CRLS content and activity.

Housed in the IMM, the oxidative phosphorylation machinery requires an
association with cardiolipin to function properly (Figure 1.2) (11, 12, 27, 29). In both the
type 1 and type 2 diabetic mouse model, data produced from our laboratory indicated
decreased ETC complex activity for complexes I, III, IV and V in the diabetic IFM and
diabetic SSM, respectively (Figure 2.4) (8, 9). Similarly in the type 2 diabetic human
heart model, ETC complex I and IV activities, as well as the protein expression of the
aforementioned complexes were decreased (Figures 3.4, 3.6 and 3.7). Data reported in
chapter 2 revealed decreased associations between cardiolipin and ATP synthase
subunits in the presence of a type 1 diabetic insult (Figure 2.6); therefore, one potential
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mechanism contributing to the decreased ETC complex activities may be the decrease
in cardiolipin content.

The dysfunctional ETC complexes can further negatively impact the IMM through
different pathways. First, the IMM is the primary source of ROS production, specifically
at ETC complex I and complex III (21); therefore, defective ETC complexes I and III
could cause an increase in ROS, which would further inhibit proper mitochondrial
function. For example, an increase in ROS can enhance the oxidative environment of
mitochondria causing stress to the organelle and its functional processes. Also, an
increase in ROS can target the double bonds composing tetralinoleic cardiolipin (Figure
1.3). This alteration in cardiolipin composition can negatively impact the interactions
between the lipid environment and important associated proteins, rendering IMM
proteins, such as ETC complexes, dysfunctional. With a lower cardiolipin content
already present during a diabetic insult, alterations to the remaining lipid environment
could severely damage cardiac mitochondria. Secondly, if the ETC complexes do not
function properly during a diabetic insult, ATP production may decrease, causing
mitochondrial dysfunction and ultimately, cardiac contractile dysfunction. Taken all
together, the results suggest possible mechanisms underlying the decreased ETC
complex activities, all of which are deleterious effects of diabetes mellitus to the IMM.

Processes housed within the IMM also require a proper membrane potential
which is generated by the IMM. Cardiolipin plays a role in membrane stability (27); and
therefore, in the maintenance of the membrane potential. Because the content of
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cardiolipin is decreased during a diabetic insult, the membrane potential becomes
unstable. Using mouse models, we have previously reported decreased membrane
potential in type 1 diabetic IFM (9), as well as in type 2 diabetic SSM (8). This decrease
in membrane potential negatively impacts the processes that are located within the
IMM, such as oxidative phosphorylation and protein import.

Glucose – mediated and fatty acid – mediated respiration were both decreased in
SSM of type 2 diabetic human atrial tissue, with no change observed in IFM (Chapter
3). These data are in partial agreement with those data that we reported previously in
the db/db mouse heart (8). In a type 1 diabetic mouse model, state 3 mitochondrial
respiration was also reported to be decreased specifically in IFM (9). Because
mitochondrial respiration relies on a membrane potential, this decrease observed in
mitochondrial respiration could be attributed in part to the decreased membrane
potential in type 1 diabetic IFM and type 2 diabetic SSM.

As depicted in Figure 1.2, the protein import machinery also resides in the IMM
and is known to interact with cardiolipin (19, 32). Both protein import activity and a key
constituent involved in the protein import process, Grp75, have been reported to be
decreased during type 1 diabetes mellitus (3). In type 2 diabetic human atrial tissue,
preliminary data examining protein import revealed decreased protein import rates in
diabetic SSM compared to a non-diabetic heart, with no effect on IFM (Figure 6.4).
Grp75 protein content was also decreased in human type 2 diabetic SSM (Figure 6.3).
The influence of diabetes on protein import and Grp75 protein levels could be altered
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due to a number of reasons. First, cardiolipin is known to be associated with the protein
import machinery (19, 32) and the decrease in cardiolipin content could subsequently
contribute to the loss in protein import activity (Chapter 2). Secondly, a loss of Grp75
protein content could either be a result of or a mechanism contributing to the decreased
protein import (Chapter 6) (3, 8). Because decreased protein import is a critical
contributor to diabetic-associated mitochondrial dysfunction, a novel transgenic mouse
line overexpressing Grp75 was generated in our laboratory (Figure 6.1).

To ensure that the Grp75 overexpressing transgenic mouse was in fact
overexpressing Grp75, we co-incubated mitochondrial subpopulations from a control
and a transgenic mouse with MitoTracker Deep Red 633, which specifically stain
respiring mitochondria, along with a Grp75-PE conjugated antibody. We subjected the
co-stained mitochondria to flow cytometry, which was able to detect the mitochondria
stained with both MitoTracker Deep Red 633 and Grp75-PE, since each dye used a
different laser to emit fluorescence. Table 6.1 depicted the results of Grp75 overexpression between a control mouse and a transgenic mouse as measured by the
mean fluorescence intensity, from which we concluded that the Grp75 mouse
overexpressed Grp75 compared to its control counterpart.

An additional method to measure Grp75 overexpression would be to perform a
Western blot; however, if Grp75 overexpression increased protein import, then the
Western blot can no longer be loaded per mitochondrial protein content because the
amount of protein between control and the transgenic mouse would more than likely not
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be equal. Therefore, the amount of intact mitochondria in each isolated sample could be
measured by selectively staining for intact mitochondria and subjecting the mitochondria
to flow cytometry (9, 34). A Western blot could then be loaded per intact mitochondria;
however, the isolated mitochondrial sample would contain not only intact mitochondria,
but also debris; therefore, without separating the debris, a Western blot would not truly
depict the amount of Grp75 protein in the overexpressing transgenic mouse. Because of
these limitations, analyzing the mean fluorescence intensity of co-stained mitochondrial
sub-populations represented the most accurate overexpression measurement.

Once the overexpression of Grp75 was established, the therapeutic benefit of
overexpressing GRP75 on mitochondrial function during a diabetic insult was evaluated.
Mitochondrial respiration is decreased in IFM during a type 1 diabetic insult (9);
however, in the presence of Grp75 overexpression, state 3 mitochondrial respiration
was restored in diabetic IFM, as seen in Figure 6.2, with no effect on state 4 or SSM.
Taken together, the preliminary data collected demonstrated that the overexpression of
Grp75 has the ability to provide cardioprotection in the presence of diabetes mellitus. In
order to fully determine the therapeutic advantage to overexpressing Grp75, cardiac
functional analyses and further mitochondrial experimentation, including protein import,
is warranted.

Table 4.1 lists the reported deleterious effects to mitochondrial subpopulation
function observed during diabetes mellitus. Taken together, the mitochondrion is
negatively impacted by diabetes mellitus regardless of the type of diabetes mellitus or
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the mitochondrial subpopulation affected. This negative impact leads to deleterious
effects to the IMM and compromising the proteins associated with the lipid environment,
specifically cardiolipin. Decreased protein import could be contributing to the loss of the
CRLS protein, from which cardiolipin content are reduced. This reduction in cardiolipin
content contributes to the dysfunctional processes housed within the IMM, including
decreased oxidative phosphorylation, as well as further exacerbation of protein import
activity. Genetic manipulation of Grp75 provided protection against diabetes-associated
mitochondrial dysfunction, possibly by preserving the IMM through restored cardiolipin
synthase protein levels and consequently, cardiolipin content. This restoration in
cardiolipin content would preserve cardiolipin-IMM protein associations, as well as key
processes required for proper mitochondrial function; however, further studies are
warranted. The preliminary data gathered from evaluating the overexpression of Grp75
may lend insight to a possible therapeutic target to alleviate the detrimental effects of
diabetes mellitus on mitochondrial function. Further, because an increase in the
oxidative environment during type 1 diabetes mellitus has been previously reported (2),
another possible beneficial treatment could be developed by targeting the antioxidant
capacity of mitochondria and inhibiting the increased oxidative environment during type
1 diabetes mellitus. Potential therapeutic strategies are further discussed in Chapter 5.
Nonetheless, the damage to the IMM signifies the importance of preserving the IMM by
developing therapeutic strategies aimed at relieving mitochondrial dysfunction.
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Table 4.1. Mitochondrial dysfunction associated with type 1 and type 2 diabetes
mellitus in mouse and human models.

State 3 Respiration (G:M)
State 4 Respiration (G:M)
State 3 Respiration (PC:M)
State 4 Respiration (PC:M)
ETC Complex I
ETC Complex III
ETC Complex IV
ETC Complex V
Cardiolipin content
Tetralinoleic cardiolipin content
Cardiolipin-key protein associations
Protein import
Grp75 content

Type 1 diabetic
mouse (STZ)

Type 2 diabetic
mouse (db/db)

Type 2 diabetic
human

SSM

SSM

IFM

SSM

IFM

↓
↓
↓
↓
↓
↓
↓

-

N/A

N/A

↓
↓
↓
↓
↓
↓
↓$*

-

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

↓

-

↓*
↓

-*
-

IFM
#

↓

-

N/A

N/A

N/A

N/A

N/A

-

↓
↓
↓
↓
↓
↓
↓
↓
↓

*Indicates preliminary data; - indicates no change; N/A indicates not measured; $ indicates a decrease
trend; and # represents preliminary restoration in the presence of Grp75 overexpression. Data collected
from our laboratory.

In conclusion, our data exemplifies the importance of recognizing that most of the
processes and subsequent proteins affected during both type 1 and type 2 diabetes
mellitus are housed within the IMM, suggesting that the IMM is targeted by diabetes
mellitus. Further, the data collected from examining mitochondrial dysfunction during a
type 1 and type 2 diabetic insult provides evidence for the importance of examining the
two mitochondrial subpopulations separately because the effects of each type of
diabetes mellitus impacts the mitochondrial subpopulations oppositely. The results of
this dissertation are in agreement with the hypothesis in that the mitochondrion is
negatively impacted by diabetes mellitus, leading to deleterious effects to the IMM and
compromising the proteins associated with cardiolipin and protein import, which
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translates to the diabetic human heart. The results of the studies in this dissertation
establish the importance preserving the IMM and those processes contained within to
alleviate mitochondrial dysfunction associated with the diabetic heart.
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Chapter 5:
Future Directions

FUTURE DIRECTIONS

Research has established an association between mitochondrial dysfunction and
the type 2 diabetic heart (2-4); however, the lipid environment, lipid-protein associations,
and specific processes contained within have not yet been examined in diabetic
mitochondrial subpopulations. Future studies examining the IMM phospholipid
environment in a mouse model of type 2 diabetes mellitus, specifically cardiolipin and
cardiolipin remodeling, would advance the understanding of the environment and the
protein interactions within, which are required for proper mitochondrial function.
Preliminary data collected for the studies included in this dissertation determined lower
cardiolipin content in type 2 diabetic SSM from human atrial tissue, which was gathered
from high performance thin layer chromatography and iodine vapor staining. A more
accurate method employing mass spectrometry would more efficiently measure the
levels of total cardiolipin content, as well as the levels of different cardiolipin species.
Data reported in chapter 2 revealed decreased interactions between cardiolipin and
ATP synthase subunits in a type 1 diabetic mouse model, specifically in IFM. These
interactions could also be measured during a type 2 diabetic insult, as well as the
interactions between cardiolipin and other proteins housed in the IMM. Together, these
results could potentially lend insight as to why some of the proteomic alterations
observed during a type 2 diabetic insult (4) may be occurring.

After revealing the negative impact of type 2 diabetes mellitus on the SSM in
human atrial tissue (Chapter 3), alterations in the mitochondrial proteome should be
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further examined. Chapter 3 included data that reported decreased ETC complex I and
IV activities in type 2 diabetic SSM. The underlying mechanism causing this decrease in
ETC complex I and IV activities was determined to be decreased protein expression of
ETC complex I and IV. Although this measurement included the ETC complex as a
whole unit, individual subunits are also more than likely affected by a type 2 diabetic
insult; therefore, this finding warrants further experimentation examining alterations in
the mitochondrial proteomic makeup during type 2 diabetes mellitus.

Preserving the IMM can be accomplished by focusing on different proteins or
processes located within the IMM. For example, during diabetes mellitus, mitochondrial
membrane potential is decreased and in conjunction with a disruption of the lipid
environment, specifically cardiolipin, a preservation strategy targeting the structure and
integrity of the IMM could prove to be beneficial in protecting mitochondrial function.
This could be through genetic manipulation of structural proteins that are altered in the
presence of diabetes mellitus. In order to conserve the IMM integrity, another strategy
could target the phospholipid environment.

Total cardiolipin content was lower in SSM of type 2 diabetic human atrial tissue
(Chapter 3), and significantly decreased in IFM of type 1 diabetic mouse hearts
(Chapter 2) along with tetralinoleic cardiolipin (5). The data in chapter 2 also revealed
decreased CRLS protein content and activity, which suggested that the decrease in
cardiolipin was due to deficient cardiolipin biosynthesis at the level of CRLS. In order to
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restore cardiolipin content, our laboratory created a genetically modified mouse model
that overexpressed CRLS (Figure 5.1).

A.

Vector Map

B.

RT-PCR

Mouse CRLS1

Figure 5.1. CRLS pCAGGS vector map. (A) Map of CLS transgenic construct using
pCAGGS. Utilization of this vector provides high levels of protein expression. (B) Real
time PCR amplification plot using a custom designed probe which amplifies the CMV
region of the CLS construct.

The CRLS construct was placed under the control of the human cytomegalovirus
immediate-early enhancer and chicken β-actin promoter with first intron. This vector
allows for high levels of protein expression (9) in all tissues, which would be beneficial
for studies using heart, skeletal or liver tissue (8). Interestingly, Kiebish et al. also
developed a mouse line that overexpressed CRLS; however, the transgene was heart
specific (7). Although Kiebish et al. did not show restored total cardiolipin levels during a
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type 1 diabetic insult as one would expect, the authors determined that tetralineolic
cardiolipin levels were restored back to normal levels, which ultimately attenuated the
mitochondrial dysfunction associated with type 1 diabetes mellitus.

Because CRLS is nuclear-encoded, another strategy that could potentially result
in increased CRLS protein content is to increase protein import rates. During type 1
diabetes mellitus, protein import rates are decreased, specifically in the diabetic IFM. By
restoring protein import rates, more CRLS could enter mitochondria and potentially
improve cardiolipin content, ultimately preserving mitochondrial function. By utilizing the
novel transgenic mouse line described in this dissertation (Chapter 4), future studies
can examine the therapeutic benefit of Grp75 overexpression on protein import rates to
determine if the import rates are rescued, which in turn could restore CRLS and other
proteins altered during a type 1 diabetic insult.

Increased ROS production is the main contributor to mitochondrial dysfunction
associated with diabetes mellitus; therefore, prevention of an enhanced oxidative
environment may lead to preservation of the IMM. For example, animal models
manipulated to overexpress players involved in the antioxidant defense system, such as
manganese superoxide dismutase, have provided protection against mitochondrial
dysfunction associated with diabetes mellitus (10). Our laboratory recently reported that
overexpression of mitochondrial phospholipid hydroperoxide glutathione peroxidase,
which is involved in the antioxidant defense system of mitochondria, restores
mitochondrial function during type 1 diabetes mellitus through scavenging lipid
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hydroperoxides (1). This model specifically could also be beneficial to the cardiolipin
environment within the IMM, by potentially restoring cardiolipin levels and ultimately,
mitochondrial function during diabetes mellitus.

Other than cardiolipin, phospholipid alterations to phospholipids housed within in
the IMM could restore functionality to a damaged IMM. For example, cardiac
mitochondrial PG content has also shown to be decreased during type 1 diabetes
mellitus (6). By creating a transgenic mouse line that overexpresses a constituent in the
biosynthetic pathway of PG, the decreased PG content may be restored. Not only would
this restoration aid in the preservation of the IMM, but PG, along with CDP-DAG, is also
hydrolyzed by CRLS to produce cardiolipin; therefore, cardiolipin levels could also be
restored. Other phospholipids housed within the IMM include, but are not limited to,
phosphatidylcholine, phosphatidylserine, and phosphatidyl-ethanolamine. If damaged
during diabetes mellitus, restoration of any of the phospholipids that compose the IMM
would be beneficial to the IMM environment and subsequent function.

The goal of this dissertation was to evaluate the impact of type 1 diabetes
mellitus on the IMM phospholipid environment, specifically cardiolipin, and the
processes that are housed within. The overall conclusion highlighted the importance of
preserving the IMM; therefore, future directions should focus on this preservation
through further examination of the impact of diabetes mellitus to the mitochondrial
proteome and processes, in order to attenuate the mitochondrial dysfunction that is
associated with diabetes mellitus.
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Chapter 6:
Appendix

Figure 6.1
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Real time PCR amplification plot

Figure 6.1. Grp75 vector map. (A.) Map of GRP75 transgenic construct housed in a
pCAGGS vector. (B.) Real time PCR amplification plot using a custom designed probe
which amplifies the CMV region of the Grp75 construct. (C.) PCR analysis was also
performed to confirm transgene presence in positive mice. N = 2.
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Figure 6.2
A.

SSM
400
300
200
100
0

B.

IFM
250
200
150

#

*

100
50
0

182

Figure 6.2. The protective benefit of Grp75 overexpression on mitochondrial
respiration. Mitochondria respiration measured in isolated mitochondria from wild-type
control (WT Ctrl), Grp75 transgenic control (TG Ctrl), wild-type diabetic (WT Diab) and
transgenic diabetic (TG Diab). (A.) SSM state 3 and state 4 respiration measured in all
four groups. (B.) IFM state 3 and state 4 respiration measured in all four groups. Key is
included. Values are presented as means ± SEM; *P < 0.05 WT Diab vs WT Ctrl. #P <
0.05 WT Diab vs TG Diab; N = 7 control wild-type control, 6 Grp75 transgenic, 9 wildtype diabetic and 6 transgenic diabetic.
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Figure 6.3
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Figure 6.3. Protein levels of Grp75 in the type 2 diabetic human heart. Western blot
analysis of protein import constituent Grp75 in non-diabetic and diabetic human heart
tissue. (A.) Representation of Grp75 protein content in SSM and in (B.) IFM. Control for
protein loading was confirmed by COXIV. Values are presented as means ± SEM; *P <
0.05 Non-diabetic vs. diabetic; N = 4.
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Figure 6.4
A.

SSM

B.

186

IFM

Figure 6.4. Preliminary protein import in the type 2 diabetic human heart. (A.)
Protein import rates between non-diabetic and diabetic human SSM. (B.) Protein import
rates between non-diabetic and diabetic human IFM. Values are presented as percent
of control. N = 1.
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Figure 6.5
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B.
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IFM

Figure 6.5. Cardiolipin content in the type 2 diabetic heart. High performance thin
layer chromatography of cardiolipin content in isolated mitochondrial subpopulations of
non-diabetics and type 2 diabetic patients. (A.) Representation of cardiolipin content in
SSM and in (B.) IFM. Values are presented as means ± SEM. Two spots represent one
sample; N = 3.
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Table 6.1
Mean Fluorescence
Intensity
SSM
Control

36.77

Transgenic Grp75

39.41

IFM
Control

42.42

Transgenic Grp75

45.92

190

Table 6.1. Grp75 overexpression in isolated mitochondrial subpopulations.
Mitochondrial subpopulations were incubated with MitoTracker Deep Red 633 and
Grp75-PE and subjected to flow cytometry. Mitochondria that were co-stained with both
dyes were analyzed. The control mean fluorescence intensity was compared to the
transgenic mean fluorescence intensity for each subpopulation. N = 1.
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